Document:

EX-10.1

 Exhibit 10.1 
 LICENSE AGREEMENT 
 between 

GLYCOMIMETICS, INC. 
 and 
 PFIZER INC. 

dated as of October 7, 2011 

 Table of Contents 

 

							
	 	  	Page No.	 
			
	 Article 1
	  	DEFINITIONS	  	 	1	  
			
	 Article 2
	  	LICENSES	  	 	11	  
			
	 Article 3
	  	DEVELOPMENT, REGULATORY AND COMMERCIALIZATION	  	 	14	  
			
	 Article 4
	  	PAYMENTS BY PFIZER TO GMI	  	 	23	  
			
	 Article 5
	  	INTELLECTUAL PROPERTY RIGHTS	  	 	30	  
			
	 Article 6
	  	CONFIDENTIALITY; PUBLICATION	  	 	32	  
			
	 Article 7
	  	REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS	  	 	37	  
			
	 Article 8
	  	INDEMNITY	  	 	42	  
			
	 Article 9
	  	TERM AND TERMINATION	  	 	46	  
			
	 Article 10
	  	NON-COMPETITION	  	 	54	  
			
	 Article 11
	  	MISCELLANEOUS	  	 	54	  

 Exhibit A – GMI Patent Rights 
 Schedule 1.10 – Backup Compounds 
 Schedule 1.22 – Structure 

Schedule 1.35 – Knowledge of GMI 

Schedule 1.69 – Format for Topline Study Report 
 Schedule 2.1 – Permitted Studies 
 Schedule 2.3 – Transition Plan

 Schedule 3.1(c) – Ongoing Clinical Trial Budget 
 Schedule 6.4 – Public Announcement 
 Schedule 7.1 – Disclosure Schedules

  
 i 

 Exhibit 10.1 
 LICENSE AGREEMENT 
 THIS LICENSE AGREEMENT dated as of
the 7th day of October, 2011 (the “Agreement”) is made between GlycoMimetics, Inc., a Delaware corporation having a place of business at 401 Professional Drive, Suite 250, Gaithersburg, Maryland 20879 (“GMI”) and Pfizer
Inc., a Delaware corporation having its principal place of business at 235 East 42nd Street, New York, New York 10017 (“Pfizer”). 
 RECITALS

 WHEREAS, GMI owns or otherwise controls the Compound (as defined below) and Licensed Product (as defined below) and GMI
desires to grant an exclusive license to Pfizer in the Territory (as defined below) with respect thereto; and 
 WHEREAS, Pfizer
has extensive experience and expertise in the development and commercialization of pharmaceutical products and desires to obtain such an exclusive license in the Territory to the Compound and the Licensed Product. 

NOW THEREFORE, in consideration of the premises and of the covenants herein contained, the Parties hereto mutually agree as follows:

 Article 1 DEFINITIONS 
 For purposes of this Agreement, the terms defined in this Article shall have the meanings specified below, whether used in their singular or plural form. 

1.1 “Additional Ongoing Clinical Trial Costs” has the meaning set forth in Section 3.1(c). 

1.2 “Additional Phase II Clinical Trial” has the meaning as set forth in Section 3.2(b). 

1.3 “Affiliate” means with respect to a Person, any Person that controls, is controlled by or is under common control
with such first Person. For purposes of this definition only, “control” means (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by
contract relating to voting rights or corporate governance, or (b) to own, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or other ownership interest of such Person.

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 1 

 
Notwithstanding the foregoing, (i) venture capital and other institutional financial investors in GMI (including venture capital and other funds, and their investors and managers), and
(ii) any Person that is under common control with GMI as a result of control of such Person and GMI by such venture capital or other financial investor in GMI of part (i), in each case, shall not be considered Affiliates of GMI for purposes of
this Agreement. 
 1.4 “Business Day” means each day of the week, excluding Saturday, Sunday, and bank or other
public holidays in New York, New York. 
 1.5 “Change of Control” means, with respect to a Party or its parent
corporation, (a) a merger or consolidation of such Party or such parent corporation with a Third Party which results in the voting securities of such Party or such parent corporation outstanding immediately prior thereto ceasing to represent at
least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger or consolidation, or (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates,
becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party or such parent corporation, or (c) the sale or other transfer to a Third Party of all or substantially all
of such Party’s assets or business or substantially all of such Party’s business which encompasses the Compound or Licensed Product. 
 1.6 “Combination Product” means a Licensed Product that in a single formulation or in a single package contains both a Compound and one or more Other Active Compounds. 

1.7 “Commercially Reasonable Efforts” means, (i) with respect to development of a Licensed Product, efforts and
resources that are reasonably sufficient, as measured by the facts and circumstances at the time such efforts and resources are carried out, to obtain Regulatory Approval in a reasonable period of time, which efforts and resources and reasonable
period of time takes into account anticipated product labeling, medical and clinical considerations, safety, efficacy and regulatory environment, and present and future market potential and other reasonably relevant factors, and (ii) with
respect to marketing and selling of a Licensed Product, efforts and resources, as measured by the facts and circumstances at the time such efforts and resources are carried out, that are consistent with present and future market potential, financial
return, labeling, channels of trade, competitive market conditions, historical performance of the Licensed Product, regulatory requirements, applicable Laws and other reasonably relevant factors. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 2 

 1.8 “Competing Product” has the meaning set forth in Article 10.

 1.9 “Completion of the Ongoing Clinical Trial” means delivery of the Topline Study Report to Pfizer by or on
behalf of GMI. 
 1.10 “Compound” means (i) GMI-1070 and all modifications, enhancements, improvements and
backups which result in a [* * *], pan selectin antagonist [* * *] and (ii) [* * *] of any of the compounds of subpart (i) of this Section 1.10 that are a [* * *], pan selectin antagonist [* * *]. For the avoidance of doubt,
Compounds include without limitation the backups specified in Schedule 1.10. 
 1.11 “Dollars” or
“$” means the legal tender of the United States. 
 1.12 “Effective Date” means the date first
hereinabove written. 
 1.13 “EMA” means the European Medicines Evaluation Agency or any successor thereto.

 1.14 “Excluded GMI Affiliate Patent Rights” means any Patent Right owned or controlled by a Future Affiliate
of GMI, to the extent, but only to the extent, that such Patent Right: 
  

	 	(i)	is not controlled by such Future Affiliate pursuant to any license or other grant of rights by GMI (or any Affiliate of GMI other than a Future Affiliate of GMI) to
such Future Affiliate; and 

  

	 	(ii)	(A) is owned or controlled by such Future Affiliate of GMI at the time such Future Affiliate becomes an Affiliate of GMI or (B) is subsequently owned or controlled
by such Future Affiliate but is developed independently of and without the use of any GMI Patent Right or GMI Know-how controlled by GMI (or any Affiliate of GMI other than a Future Affiliate of GMI) at the time such Future Affiliate becomes an
Affiliate of GMI. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 3 

 1.15 “FDA” means the United States Food and Drug Administration or any
successor agency in the United States with responsibilities comparable to those of the United States Food and Drug Administration. 
 1.16 “Field” means any and all fields of use. 
 1.17
“First Commercial Sale” means the first sale of a Licensed Product by (i) Pfizer or its Affiliate or Sublicensee or (ii) with respect to Section 9.6, GMI or its Affiliates or Sublicensee, in each case to a Third Party
in a country following Regulatory Approval (to the extent necessary for commercial sale, and, in any country in which Pricing Approval is necessary or relevant for a majority of the population to obtain access to pharmaceutical products, Pricing
Approval) of such Licensed Product in such country. 
 1.18 “First Indication” means Sickle Cell Disease.

 1.19 “Future Affiliate” means, with respect to either Party, a Third Party that is not an Affiliate of such
Party as of the Effective Date but that subsequently becomes an Affiliate of such Party as a result of a Change of Control of such Party. 
 1.20 “GAAP” means United States generally accepted accounting principles as applicable to each Party, consistently applied. 

1.21 “Generic Product” means any pharmaceutical product that (i) is sold by a Third Party that is not a licensee or
Sublicensee of Pfizer or its Affiliates, or any of their licensees or Sublicensees under a marketing authorization granted by a Regulatory Authority to such Third Party, and (ii) contains the same Compound as an active pharmaceutical ingredient
as the relevant Licensed Product and (x) for purposes of the United States, is approved through an Abbreviated New Drug Application or successor or similar process by reliance on the prior approval of a Licensed Product as determined by the
FDA, or (y) for purposes of a country outside the United States, is approved through an abbreviated process in reliance on the prior approval of a Licensed Product as determined by the applicable Regulatory Authority. 

1.22 “GMI-1070” means each of the compounds described in Schedule 1.22, [* * *]. 

1.23 “GMI Excluded Patent Rights” means Patent Rights owned by GMI that cover an Other Active Compound and/or
manufacture or use thereof independent of a Compound. 
 1.24 “GMI Indemnitees” has the meaning set forth in
Section 8.1. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 4 

 1.25 “GMI Know-How” means (i) Know-How owned by or licensed to GMI as
of the Effective Date and (ii) Know-How owned by GMI after the Effective Date that is developed prior to Completion of the Ongoing Clinical Trial, obtained as a result of or in connection with any trials with respect to the Compound, and in
either case which is useful for the manufacture, research or development of any Compound. 
 1.26 “GMI Net
Sales” means with respect to a Licensed Product, the gross amount invoiced by GMI and/or its Affiliates and/or its sublicensees of such Licensed Product to Third Parties, less (i) [* * *] and (ii) [* * *]. In the case of
Combination Products: (1) if GMI and/or its Affiliates and/or its sublicensees of such Licensed Product [* * *] and [* * *], the GMI Net Sales attributable to such Combination Product during such year shall be calculated by [* * *]; (2) if
GMI and/or its Affiliates and/or its sublicensees of such Licensed Product [* * *], the GMI Net Sales attributable to such Combination Product during such year shall be calculated by [* * *]; and (3) if GMI and/or its Affiliates and/or it
sublicensees of such Licensed Product [* * *], then the GMI Net Sales attributable to such Combination Product shall be [* * *]; provided, that the quarterly report provided by GMI with respect to GMI Net Sales in accordance with
Section 9.6 shall include the calculations for subclauses (1), (2) and (3) above. 
 GMI Net Sales shall be
determined from the books and records maintained in accordance with GAAP, as consistently applied by GMI. The calculation of GMI Net Sales will involve the use of estimates for certain deductions above. Those estimates will be accrued and GMI Net
Sales trued-up at least quarterly to actual in accordance with GAAP and GMI’s internal accounting policies, as consistently applied. 
 1.27 “GMI Patent Rights” means Patent Rights, other than Excluded GMI Affiliate Patent Rights, (i) owned by GMI or licensed to GMI with the right to grant a sublicense, in each case
as of the Effective Date and in each case to the extent such Patent Rights cover a Compound or the manufacture or use thereof and/or a Licensed Product and/or the manufacture or use thereof, but excluding claims that cover an Other Active Compound
and/or manufacture or use thereof independent of a Compound and (ii) Patent Rights that are not GMI Excluded Patent Rights and are owned by GMI after the Effective Date and prior to the end of the Term, in each of the foregoing cases to the
extent such Patent Rights cover a Compound or the manufacture or use thereof and/or a Licensed Product and/or the manufacture or use thereof, and wherein the GMI Patent Rights defined herein include those set forth in Exhibit A which shall be
supplemented as necessary by GMI. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 5 

 1.28 “Governmental Authority” means any court, agency, department,
authority or other instrumentality of any national, state, county, city or other political subdivision. 
 1.29
“Indemnitee” has the meaning set forth in Section 8.3. 
 1.30 “IND” means an
Investigational New Drug, Application or similar application or submission for approval to conduct human clinical investigations that is filed or submitted to a Regulatory Authority. 

1.31 “Invention” means all inventions, discoveries, improvements and other technology, whether or not patentable.

 1.32 “JDT” has the meaning set forth in Section 3.1. 

1.33 “JSC” has the meaning set forth in Section 3.2(b). 

1.34 “Know-How” means ideas, writings, data (including but not limited to pre-clinical and clinical data), methods,
techniques, materials, information (including scientific and technical information), know-how, assays, compounds, and Inventions and the rights thereto other than Patent Rights, including but not limited to manufacturing and formulation information,
whether or not patentable. 
 1.35 “Knowledge” means with respect to a Party, the actual knowledge of the
officers and agents of such Party, without conducting an investigation other than making inquiries of their attorneys. The officers and agents of GMI with respect to this definition are limited to those individuals listed on Part A of Schedule 1.35,
and the attorneys as to which GMI made inquiries are limited to those on Part B of Schedule 1.35. 
 1.36 “Law”
or “Laws” means all laws, statutes, rules, regulations, orders, judgments and/or ordinances of any Governmental Authority. 
 1.37 “Licensed Product” means (a) the Compound and (b) any pharmaceutical product, in all dosage forms and formulations, that contains a Compound the manufacture, sale, offer
for sale, importation, or use of which (i) is covered by a Valid Claim of GMI Patent Rights and/or (ii) embodies or incorporates GMI Know-How or is derived or results from the use of GMI Know-How. For the avoidance of doubt, “Licensed
Product” shall also collectively refer to Combination Product. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 6 

 1.38 “Litigation Conditions” has the meaning set forth in Section 8.4.

 1.39 “Losses” has the meaning set forth in Section 8.1. 

1.40 “Major Country of Europe” means each of [* * * ] and [* * *]. 

1.41 “Net Sales” means, with respect to a Licensed Product, the gross amount invoiced by Pfizer, its Affiliates and its
Sublicensees for such Licensed Product to Third Parties, less (i) [* * *] and (ii) [* * *]. In the case of Combination Products: (1) if Pfizer and/or its Affiliates or Sublicensees [* * *], the Net Sales attributable to such
Combination Product during such year shall be calculated by [* * *]; (2) if Pfizer and/or its Affiliates or Sublicensees [* * *], the Net Sales attributable to such Combination Product during such year shall be calculated [* * *]; and
(3) if Pfizer and/or its Affiliates or Sublicensees [* * *], then the Net Sales attributable to such Combination Product shall be [* * *]; provided, that the quarterly report provided by Pfizer with respect to Net Sales in accordance
with Section 4.3 shall include the calculations for subclauses (1), (2) and (3) above and GMI shall have the right to audit such calculations as set forth in Section 4.4. 

Net Sales shall be determined from the books and records maintained in accordance with GAAP, as consistently applied by Pfizer. The
calculation of Net Sales will involve the use of estimates for certain deductions above. Those estimates will be accrued and Net Sales trued-up at least quarterly to actual in accordance with GAAP and Pfizer’s internal accounting policies, as
consistently applied. 
 1.42 “Ongoing Clinical Trial” means the Phase II Clinical Trial being performed by GMI
with respect to GMI-1070 under Protocol GMI-1070-201. 
 1.43 “Other Active Compound” means a therapeutically
active compound that is not a Compound. 
 1.44 “Party” means GMI or Pfizer and collectively the
“Parties”. 
 1.45 “Patent Rights” means United States and foreign counterpart patents, patent
applications, provisional patent applications, certificates of invention, applications for certificates of invention, divisions, continuations, continuations-in-part, non-provisional patent applications

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 7 

 
claiming priority benefit of a provisional application, continued prosecution applications, national and regional stage counterparts, together with any patent term extensions, registrations,
confirmations, reissues, re-examinations or renewals and supplemental examinations of the foregoing as well as supplementary protection certificates or the equivalent thereof, and any other form of government-issued patent protection directed to the
inventions claimed in the foregoing. 
 1.46 “Person” means an individual, sole proprietorship, partnership,
limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or
political subdivision, department or agency of a government. 
 1.47 “Pfizer Excluded Patent Rights” means
Patent Rights owned by or licensed to Pfizer or its Affiliates that cover an Other Active Compound and/or manufacture or use thereof independent of a Compound. 
 1.48 “Pfizer Indemnitees” has the meaning set forth in Section 8.2. 
 1.49 “Pfizer Know-How” means Know-How owned by or licensed to Pfizer or its Affiliates (with the right to grant sublicenses) as of the date of termination covered by Section 9.5
which (a) constitute improvements to Compound or Licensed Product or the manufacture or use thereof, where such improvements were created or made in the course of activities carried out pursuant to the licenses granted to Pfizer in
Section 2.1, or (b) Pfizer had actually applied or used with respect to a Compound or Licensed Product prior to any termination of this Agreement, provided that such Know-How is necessary or useful for the continued research, development,
manufacture or commercialization of such Compound or Licensed Product in the Reference Forms, or (ii) Pfizer had, prior to any termination of this Agreement, incorporated into such Compound or Licensed Product in the Reference Forms as of the
time of such termination. 
 1.50 “Pfizer Patent Rights” means Patent Rights owned by Pfizer or its Affiliates
or licensed to Pfizer or its Affiliates (with the right to grant sublicenses) that are not Pfizer Excluded Patent Rights, in each case as of the date of termination covered by Section 9.5 of this Agreement and in each case to the extent such
Patent Rights (a) cover improvements to a 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 8 

 
Compound or the manufacture or use thereof and/or improvements to a Licensed Product and/or the manufacture or use thereof, in each case described in this clause (a) where such improvement
was created or made in the course of activities carried out pursuant to the licenses granted to Pfizer in Section 2.1, or (b) cover a product, composition or process that (i) Pfizer had actually applied or used with respect to a
Compound or Licensed Product prior to any termination of this Agreement, provided that such a product, composition or process is necessary or useful for the continued research, development, manufacture or commercialization of such Compound or
Licensed Product in the Reference Forms as of the time of such termination, or (ii) Pfizer had, prior to any termination of this Agreement, incorporated into such Compound or Licensed Product in the Reference Forms as of the time of such
termination. 
 1.51 “Pfizer Quarter” means (i) in the United States, each of the four (4) thirteen
(13) week periods as used by Pfizer in its audited financial reports, the first commencing on January 1 of any year, and (ii) in any country in the Territory other than the United States, each of the four (4) thirteen
(13) week periods as used by Pfizer in its audited financial reports, the first commencing on December 1 of any year. With respect to Net Sales, the Net Sales for a Pfizer Quarter is the aggregate of Net Sales in the United States and
outside the United States for the applicable Pfizer Quarter. 
 1.52 “Pfizer Year” means the twelve
(12) month period (i) with respect to the United States, commencing on January 1st of any calendar year and (ii) with respect to any country in the Territory other than the United States, commencing on December 1st of any
calendar year. 
 1.53 “Phase II Clinical Trial” means for the purpose of obtaining Regulatory Approval a study
in humans of the safety, dose range and efficacy of a Product that is prospectively designed to generate sufficient data to commence a Phase III Clinical Trial that would satisfy the requirements of 21 C.F.R. 312.21(b), or the equivalent process in
other countries or groups of countries of the Territory. 
 1.54 “Phase III Clinical Trial” means a controlled
study in humans of the efficacy and safety of a Product that is prospectively designed to demonstrate statistically whether such Product is effective and safe for use in a particular indication in a manner sufficient to obtain Regulatory Approval to
market such Product that would satisfy the requirements of 21 C.F.R. 312.21(c), or the equivalent process in other countries or groups of countries of the Territory. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 9 

 1.55 “Phase III Milestone Advance” has the meaning set forth in
Section 4.1(c). 
 1.56 “Pricing Approval” means, in any country where a Governmental Authority authorizes
reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or
determination (as the case may be). 
 1.57 “Product Infringement” has the meaning set forth in
Section 5.2(b). 
 1.58 “Reference Form” means a Compound or Licensed Product (i) in the form being
sold by Pfizer at the time of termination of this Agreement covered by Section 9.5, and/or (ii) in the form used in any ongoing clinical trial at the time of termination of this Agreement covered by Section 9.5 and/or (iii) in
the form used in a clinical trial completed by Pfizer at the time of termination of this Agreement covered by Section 9.5. 

1.59 “Regulatory Approval(s)” means any and all approvals, with respect to any jurisdiction, or authorizations (other
than Pricing Approvals) of a Regulatory Authority, that are necessary for the commercial manufacture, distribution, use, marketing or sale of a pharmaceutical product in such jurisdiction. 

1.60 “Regulatory Authority” means, in respect of a particular country or jurisdiction, the Governmental Authority having
responsibility for granting Regulatory Approvals in such country or jurisdiction, including in the United States the FDA, and any successor governmental authority having substantially the same function. 

1.61 “Second Indication” means any indication other than the First Indication. 

1.62 “Sickle Cell Disease” means sickle cell disease or sickle cell anemia, a chronic anemia marked by sickle-shaped red
blood cells occurring in individuals who are homozygous for a mutant hemoglobin gene. 
 1.63 “Sublicensee”
means any person or entity that is granted a sublicense by Pfizer under the license granted to Pfizer pursuant to this Agreement. 
 1.64 “Term” has the meaning set forth in Section 9.1. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 10 

 1.65 “Territory” means the entire world. 

1.66 “Third Party” means any entity other than GMI or Pfizer and any respective Affiliates. 

1.67 “Third Party Claim” has the meaning set forth in Section 8.4. 

1.68 “Third Party Royalty” has the meaning set forth in Section 4.2(c). 

1.69 “Topline Study Report” means a summary of results, including data tables, with respect to the Ongoing Clinical
Trial, in the form attached in Schedule 1.69. 
 1.70 “Transition Plan” has the meaning set forth in
Section 2.3. 
 1.71 “United States” or “U.S.” means the United States of America and its
territories and possessions. 
 1.72 “Valid Claim” “ means, with respect to a particular country, an
issued claim of an unexpired granted patent which claim (i) has not been cancelled, withdrawn, abandoned, or disclaimed, and (ii) has not been permanently revoked, held invalid or unenforceable by a decision of a court of competent
jurisdiction or administrative agency in an unappealed or unappealable decision in the subject country, and (iii) has not been admitted to be invalid or unenforceable through reissue or otherwise. 

1.73 “Withholding Party” has the meaning set forth in Section 4.5. 

Article 2 LICENSES 
 2.1 Exclusive License. Subject to the terms of this Agreement, GMI hereby grants to Pfizer an exclusive license or sublicense (even as to GMI), as the case may be, with the right to grant
sublicenses pursuant to Section 2.2, under GMI Patent Rights and GMI Know-How to research, develop, make, have made, use, sell, offer to sell, supply, cause to be supplied, import and have imported Licensed Product in the Field in the
Territory. GMI covenants and agrees that neither GMI nor its Affiliates will practice, use or exploit GMI Patent Rights and/or GMI Know-How with respect to Compound, except in performing and completing the Ongoing Clinical Trial and for carrying out
or allowing Third Parties to carry out the studies described in Schedule 2.1. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 11 

 2.2 Right to Sublicense. Within its sole discretion, Pfizer may grant exclusive or
non-exclusive sublicenses under any of the rights and licenses granted to Pfizer under Section 2.1 of this Agreement subject to the following conditions: (i) each sublicense shall be subject to and consistent with the rights and licenses
granted under this Agreement; (ii) each sublicense shall include an obligation of the Sublicensee to account for and report its sales of Licensed Products to Pfizer on the same basis as if such sales were Net Sales by Pfizer; and
(iii) each sublicense shall require the Sublicensee to be bound by the terms and conditions of this Agreement (other than payment provisions for which Pfizer is responsible) as if the Sublicensee was a signatory to this Agreement. Pfizer shall
provide GMI with prompt written notice that a sublicense has been granted or terminated. The name of the Sublicensee and a copy of the sublicense agreement and any amendments thereto, which agreements and amendments shall be redacted as to any
financial and other proprietary information, shall be furnished by Pfizer to GMI within thirty (30) days after the execution thereof. Pfizer shall cause a Sublicensee to comply with the terms and conditions of this Agreement and Pfizer shall be
liable to GMI for any breach of such terms and conditions by any Sublicensee. 
 2.3 Disclosure of Technology.

 (a) GMI shall provide to Pfizer the GMI Know-How and a copy of filings, minutes and correspondence with a
Regulatory Authority in its possession that may be necessary or useful to Pfizer to develop, manufacture, register, or market Licensed Products and efficiently practice the licenses granted under this Agreement within sixty (60) days of the
Effective Date and thereafter (to the extent not previously disclosed and provided) no later than twenty (20) Business Days after such additional GMI Know-How becomes known or is acquired and a copy of filings, minutes and correspondence with a
Regulatory Authority no later than twenty (20) Business Days after made, and after Completion of the Ongoing Clinical Trial, GMI shall transfer to Pfizer (i) within ten (10) Business Days after database lock for the Ongoing Clinical
Trial all INDs and other filings, minutes and correspondence with a Regulatory Authority, and (ii) within a reasonable period of time after Completion of the Ongoing Clinical Trial, but in any event within ten (10) Business Days after
receiving such information from the relevant service providers, any safety or pharmacovigilance databases, in each case, with respect to Licensed Product in the Territory. GMI shall bear its costs and expense for providing to Pfizer all of the
information described above in this Section 2.3. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 12 

 (b) In order to ensure the smooth transition of such GMI Know-How and
development activities to Pfizer for the Compounds and Licensed Products that GMI has licensed to Pfizer pursuant to Section 2.1, each Party shall, at its own cost and expense (except as expressly set forth in the Schedule 2.3), carry out the
activities to be performed by it as set forth in the transition plan attached hereto as Schedule 2.3 (the “Transition Plan”). If there is an inconsistency or disagreement between the Transition Plan and this Agreement, the terms of
this Agreement shall prevail. Neither this Agreement nor the licenses granted hereunder shall be construed to confer any rights or licenses to Pfizer by implication, estoppel or otherwise as to any data, Know-How or Patent Rights other than GMI
Patent Rights and GMI Know-How in accordance with the licenses granted under this Agreement. 
 (c) In addition
to providing the information described in Section 2.3(a) and the transition services described in Section 2.3(b), at the request of Pfizer, GMI shall provide Pfizer with reasonable technical assistance with respect to understanding and
implementing the GMI Know-How and filings, minutes and correspondence with a Regulatory Authority provided to Pfizer under the foregoing provisions of this Section 2.3; provided, however, that in providing assistance under this
Section 2.3(c), GMI shall provide [* * *] of meetings between the appropriate GMI representatives and Pfizer representatives and an additional [* * *] of GMI representatives at no cost to Pfizer, and Pfizer shall pay GMI on a person-hour basis
for any additional assistance under this Section 2.3(c) at a rate and for a number of hours that will be agreed upon in advance between GMI and Pfizer. 
 2.4 Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information. Subject to the terms and conditions of this Agreement and any preexisting exclusive license grants
to Third Parties, and without limiting any other license granted to either Party under this Agreement: 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 13 

 (a) GMI hereby grants to Pfizer a non-exclusive, irrevocable, perpetual,
royalty-free, fully paid-up, worldwide license, with the right to sublicense to Pfizer Affiliates, to use only for research purposes any and all GMI Know-How or Confidential Information of GMI disclosed to Pfizer during the Term but not any GMI
Patent Rights, it being understood and agreed that neither Pfizer nor any of its Affiliates will have any right or license under this Section 2.4 to use any such GMI Know-How or GMI Confidential Information with respect to Compound or Licensed
Product after termination of this Agreement and/or in connection with obtaining Regulatory Approval of a pharmaceutical product and/or the sale or manufacture for sale of any pharmaceutical product. 

(b) Pfizer hereby grants to GMI a non-exclusive, irrevocable, perpetual, royalty-free, fully paid-up, worldwide license,
with the right to sublicense to GMI Affiliates, to use only for research purposes any and all Pfizer Know-How or Confidential Information of Pfizer disclosed to GMI during the Term (but not any Pfizer Patent Rights ), it being understood and agreed
that neither GMI nor any of its Affiliates will have any right or license under this Section 2.4 to use any such Pfizer Know-How or Pfizer Confidential Information in connection with obtaining Regulatory Approval of a pharmaceutical product
and/or the sale or manufacture for sale of any pharmaceutical product. 
 Article 3 DEVELOPMENT, REGULATORY AND
COMMERCIALIZATION 
 3.1 Completion of the Ongoing Clinical Trial. 

 

	 	(a)	Supervision and Control. 

 (i) Subject to subsections (ii) and Section 3.1(b) and 3.1(c), GMI shall complete the Ongoing Clinical Trial as soon as reasonably practicable after the Effective Date at the cost and expense of
GMI and under the supervision and control of the JDT (as defined below); provided, that such supervision and control of the JDT is in accordance with applicable Laws and is in conformance with GMI’s obligations under any agreements with
a Third Party that exist as of the Effective Date. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 14 

 (ii) Notwithstanding Section 3.1(a)(i), GMI shall not be required to
continue the Ongoing Clinical Trial in the event that GMI reasonably believes that continuing the Ongoing Clinical Trial raises concerns about patient safety and/or would be in violation of any applicable Law; provided, that GMI shall
promptly notify Pfizer in writing of any such decision to discontinue the Ongoing Clinical Trial and Pfizer shall be required to provide its written consent for such discontinuation, which consent shall not be unreasonably withheld. 

 

	 	(b)	Joint Development Team. 

 (i) Purpose. Within thirty (30) days after the Effective Date, the Parties shall establish a Joint Development Team (“JDT”) for the purpose of supervising and controlling the
Ongoing Clinical Trial, including but not limited to (i) reviewing and approving all development, regulatory and pharmaceutical sciences plans and all material changes thereto, (ii) reviewing and approving the scientific integrity,
statistical analysis plans and protocols of the Ongoing Clinical Trial and (iv) reviewing and discussing data and results, including with respect to safety issues, of the Ongoing Clinical Trial. The JDT shall be composed of six (6) members
(or such other number as mutually agreed in writing by the Parties) with three (3) members designated by each Party in writing to the other Party, who each are employees or contracted consultants of their respective Parties and have the
appropriate expertise and authority to participate in the activities and decision-making of the JDT. The JDT shall appoint a chairperson from among its members, which shall be one of the representatives of Pfizer. The chairperson shall be
responsible for calling meetings of the JDT and for leading the meetings. The JDT shall not have the power to make any amendments or modifications to this Agreement. The JDT shall be disbanded upon the Completion of the Ongoing Clinical Trial.

 (ii) Meetings and Information Requests. The JDT shall meet within twenty (20) Business Days after
the Effective Date and, thereafter, once each month or more frequently if requested by the chairperson in writing. A quorum for the conduct of 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 15 

 
business at any meeting of the JDT shall consist of one representative of Pfizer and one representative of GMI. Each of Pfizer and GMI, shall have one vote, and subject to clause
(iii) below, all decisions shall be reached by a unanimous vote. If a JDT member, including the Chairperson, cannot attend a JDT meeting, such member may send a designate who is authorized to make decisions on behalf of the respective Party,
and such designate shall be permitted to participate fully in such JDT meeting, including casting any required vote. Upon prior written notice, each Party may invite additional employees of such Party to attend any JDT meeting to the extent that
such Party believes that attendance by one or more additional employees is necessary or desirable to fulfill the purpose of the JDT. The location of meetings of the JDT shall alternate between Pfizer’s and GMI’s principal place of
business, or shall be conducted by telephone and/or video conferencing as agreed by the Parties. Each Party shall bear its own expenses related to the attendance at JDT meetings. 

In the event that Pfizer requests additional information from GMI with respect to the Ongoing Clinical Trial that is in
the possession or control of GMI (including information controlled by GMI but in the possession of a Third Party), GMI shall provide such information to Pfizer and to the extent reasonably possible such information shall be provided within three
(3) Business Days of such request, provided, however, that GMI shall promptly provide Pfizer with any information with respect to any safety issues. 
 (iii) Decision-Making. In the event that there is a tie vote that is not resolved by the Parties within ten (10) days after the tie vote, then the vote shall be resolved by Pfizer. 

(iv) Minutes. The JDT shall keep accurate minutes of its deliberations which shall record all proposed decisions
and all actions recommended or taken. A member of the JDT shall serve as secretary and the Parties shall alternate responsibility for the preparation of the draft minutes on a calendar quarter basis. Draft minutes shall be sent to all members of the
JDT within fifteen (15) days after each meeting and shall be approved, if appropriate, or amended and approved as amended within thirty (30) days by a quorum of the JDT. All records of the JDT shall at all times be available to both Pfizer
and GMI. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 16 

	 	(c)	Costs for Completion of the Ongoing Clinical Trial. 

  

	 	A.	The budget for the costs for Completion of the Ongoing Clinical Trial after the Effective Date is set forth in Schedule 3.1(c). In the event that GMI anticipates that
the costs for Completion of the Ongoing Clinical Trial after the Effective Date is reasonably likely to exceed [* * *] Dollars ($[* * *]), GMI shall promptly notify the JDT. If GMI anticipates that total costs will exceed [* * *] Dollars ($[* * *]),
GMI shall promptly submit to the JDT for approval a new budget for such costs, together with a detailed explanation of the estimated excess costs. Such new budget must be approved by the JDT prior to the incurrence of any costs in excess of [* * *]
Dollars ($[* * *]). GMI shall be responsible for the costs for Completion of the Ongoing Clinical Trial after the Effective Date, provided that the total costs payable by GMI after the Effective Date for Completion of the Ongoing Clinical Trial
shall not exceed [* * *] Dollars ($[* * *]). Notwithstanding anything else to the contrary, GMI shall have the right to suspend any and all work with respect to the Ongoing Clinical Trial to the extent that the cost thereof after the Effective Date
exceeds [* * *] Dollars ($[* * *]) until the JDT approves a revised budget for the costs of Completion of the Ongoing Clinical Trial as set forth above (such excess costs, the “Additional Ongoing Clinical Trial Costs”). On an
ongoing basis, and no more than [* * *], Pfizer shall reimburse GMI [* * *] such Additional Ongoing Trial Costs and payment shall be due from Pfizer within [* * *] after receipt of an invoice and an explanation of the Additional Ongoing Clinical
Trial Costs included in the invoice. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 17 

	 	B.	In the event that the Additional Ongoing Clinical Trial Costs due and payable by Pfizer hereunder exceed $[* * *], Pfizer shall have the right, after Completion of the
Ongoing Clinical Trial, to engage an independent certified public accounting firm selected by Pfizer and reasonably acceptable to GMI, at Pfizer’s expense, except as set forth below, and upon at least forty-five (45) days prior written
notice and no later than [* * *] after Completion of the Ongoing Clinical Trial, to have access during normal business hours to such of the records of GMI as may be reasonably necessary to verify the accuracy of the Additional Ongoing Clinical Trial
Costs paid by Pfizer hereunder. The accounting firm shall disclose to Pfizer and GMI only whether the Additional Ongoing Clinical Trial Costs are correct or incorrect and the amount of any discrepancy. If such accounting firm identifies an
overpayment of such Additional Ongoing Clinical Trial Costs, GMI shall reimburse to Pfizer the amount of the overpayment within thirty (30) days of the date Pfizer delivers to GMI such accounting firm’s written report so concluding. The
fees charged by such accounting firm shall be paid by Pfizer unless the overpayment exceeded [* * *] percent ([* * *]%) of the amount invoiced by GMI with respect to the Additional Ongoing Clinical Trial Costs, in which case, GMI shall pay to Pfizer
the fees and costs charged by such accounting firm. 

 3.2 Development Activities, Regulatory Approval and
Commercialization After the Completion of the Ongoing Clinical Trial. 
 (a) Diligence. After
Completion of the Ongoing Clinical Trial, Pfizer agrees to use Commercially Reasonable Efforts to, at its expense, develop, obtain Regulatory Approval for commercialization and continue to commercialize a Licensed Product for the First Indication in
the United States. Pfizer shall notify GMI in writing promptly of any decision to cease development activities, efforts to obtain Regulatory Approval, or commercialization of the Licensed Product for the First Indication in the United States and the
Major Countries of Europe. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 18 

 (b) Development Activities and Regulatory Affairs. 

(i) Development Activities. 

(A) As between GMI and Pfizer, Pfizer shall have the exclusive right and responsibility, at Pfizer’s own expense, to
develop any Compounds and Licensed Products after Completion of the Ongoing Clinical Trial. As between GMI and Pfizer, all decisions with respect to development activities for any Compounds and Licensed Products after Completion of the Ongoing
Clinical Trial shall be made by Pfizer. 
 (B) Without limiting the foregoing, after the Completion of the
Ongoing Clinical Trial, as between GMI and Pfizer, Pfizer shall have the sole right to determine whether Pfizer or a Regulatory Authority requires an additional Phase II Clinical Trial (an “Additional Phase II Clinical Trial”) for
Licensed Products with respect to the First Indication, and if such determination is made, to initiate and complete such Additional Phase II Clinical Trial. 
 (ii) Regulatory Affairs. 
 (A) As between GMI and Pfizer,
Pfizer shall have the sole right, at Pfizer’s own expense, to determine all regulatory plans and strategies for the Licensed Products, and will own and be responsible for preparing, seeking, submitting and maintaining all regulatory filings and
Regulatory Approvals for all Licensed Products, including but not limited to, (A) preparing all reports necessary as part of a regulatory filing or Regulatory Approval, (B) having the sole right to determine whether to file for Regulatory
Approval in any country in the Territory, and (C) obtaining Regulatory Approval in any country in the Territory. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 19 

 (B) As between GMI and Pfizer, Pfizer shall have the sole right to apply
for and secure exclusivity rights that may be available under the Law of countries in the Territory, including any data or market exclusivity periods such as those periods listed in the FDA’s Orange Book or periods under national
implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 (including any pediatric exclusivity extensions or other forms of regulatory exclusivity that may be available), and all international equivalents. GMI shall reasonably cooperate with
Pfizer and take such reasonable actions to assist Pfizer, in obtaining such exclusivity rights in each country, as Pfizer may reasonably request from time to time. 

(iii) Joint Steering Committee. 

(A) Purpose. Within thirty (30) days after the Completion of the Ongoing Clinical Trial, the Parties shall
establish a Joint Steering Committee (“JSC”) for the purpose of exchanging information and reporting on the progress of the development of Licensed Product including but not limited to, clinical trials, as well as regulatory,
manufacturing, safety and efficacy issues and, at the relevant time, discussing at a high level Pfizer’s plans for the initial launch of the Licensed Product (provided that in no event shall Pfizer be obligated to provide detailed
commercialization plans or sensitive commercial information except as set forth in Section 4.3 or 4.4). For the avoidance of doubt, the JSC shall be a non-voting entity and no votes or decisions shall be made by its members. The JSC shall be
composed of at least two (2) members (or such other number as mutually agreed in writing by the Parties) designated by each Party in writing to the other Party, who each are employees or contracted consultants of their respective Parties and
have the appropriate expertise and authority to participate in the activities. The JSC shall appoint a chairperson from among its members, which shall 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 20 

 
be one of the representatives of Pfizer. The chairperson shall be responsible for calling meetings of the JSC and for leading the meetings. At each meeting of the JSC, Pfizer will provide the JSC
with updates as to plans for researching and developing Licensed Product and including an update on work performed with respect to Licensed Product during the previous calendar quarter. The JSC shall not have the power to make any amendments or
modifications to this Agreement. The JSC shall be disbanded upon the earlier of (i) Regulatory Approval by the FDA of a Licensed Product for the First Indication in the United States or (ii) a Change of Control of GMI or (iii) upon
prior written notice by GMI to Pfizer. 
 (B) Meetings. The JSC shall meet within forty-five
(45) days after the Completion of the Ongoing Clinical Trial and, thereafter, at least every six (6) months or more frequently if requested by the chairperson in writing. Each Party shall have at least one designated representative in
attendance at any JSC meeting and each Party may invite additional employees of such Party to attend any JSC meeting to the extent that such Party believes that attendance by one or more additional employees is necessary or desirable to fulfill the
purpose of the JSC. If a JSC member cannot attend a JSC meeting, such member may send a designate, and such designate shall be permitted to participate fully in such JSC meeting. The location of meetings of the JSC shall alternate between
Pfizer’s and GMI’s principal place of business, or shall be conducted by telephone and/or video conferencing as agreed by the Parties. Each Party shall bear its own expenses related to the attendance at JSC meetings. 

(C) Minutes. The JSC shall keep accurate minutes of its discussions held at each meeting. A JSC member of Pfizer
shall serve as secretary of JSC meetings. The secretary of the meeting shall prepare and distribute to all members of the JSC minutes of the meeting within thirty (30) days after each meeting and shall be approved, or revised and approved at
the next JSC meeting. All records of the JSC shall at times be available to both Pfizer and GMI. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 21 

 (iv) Pfizer Reports. Following such time as the JSC is disbanded,
Pfizer shall provide GMI with a written report summarizing in reasonable detail the development and/or regulatory activities performed by Pfizer and its Affiliates and Sublicensees as to research and development of a Licensed Product for each [* *
*], within [* * *] days after the end of each [* * *]. Such report shall be provided by Pfizer to GMI through, and with respect to, the first calendar year after the First Commercial Sale in the United States. Thereafter upon GMI’s
request no more frequently than [* * *], Pfizer shall provide to GMI and update with respect to any ongoing or planned clinical trials of any Licensed Product (including clinical trials for any new indications) undertaken by or on behalf of Pfizer
or any of its Affiliates and any pending or planned applications for Regulatory Approval for the Licensed Product by or on behalf of Pfizer or any of its Affiliates (including applications with respect to any new indications for the Licensed
Product). 
 (c) Commercialization/Pricing. 

(i) General. Pfizer shall be solely responsible for, at Pfizer’s expense, marketing, promoting, selling,
distributing and determining pricing and other terms of sale for all Licensed Products. 
 (ii)
Trademarks. The Licensed Products shall be sold under a trademark, and marketed using logos, trade dress and domain names selected and owned by Pfizer. Applications for all such product trademarks shall be filed, registered, maintained and
prosecuted by Pfizer, at Pfizer’s expense. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 22 

 (d) Manufacture and Supply. Pfizer shall be responsible for the
manufacture and supply of (i) clinical materials for an Additional Phase II Clinical Trial initiated after the Completion of the Ongoing Clinical Trial and any Phase III Clinical Trial for each Licensed Product and (ii) for the commercial
supply of each Compound and each Licensed Product in the Territory. 
 Article 4 PAYMENTS BY PFIZER TO GMI 

4.1 Milestone Payments. 
 (a) Effective Date Payment. In partial consideration for the expenses incurred by GMI in research and development of Licensed Product prior to the Effective Date, Pfizer shall pay GMI twenty-two
million five-hundred thousand dollars ($22,500,000) within fifteen (15) days after the Effective Date, which payment shall be non-refundable and non-creditable. 

(b) Event Milestones. Pfizer shall pay to GMI the following non-creditable, except as set forth in this Agreement,
non-refundable amounts within forty-five (45) days of the first occurrence and only the first occurrence of the following events in connection with a Licensed Product that is achieved by Pfizer or its Affiliate or Sublicensee: 

(i) With respect to [* * *]: 
  

					
	(A)	  	Subject to [* * *], initiation of dosing of a first patient in a first Phase III Clinical Trial for the First Indication	  	$35,000,000
			
	(B)	  	Acceptance of filing for Regulatory Approval by the FDA for the First Indication	  	$[* * *]
			
	(C)	  	First Commercial Sale in the United States for the First Indication	  	$[* * *]
			
	(D)	  	Acceptance of filing for Regulatory Approval by the EMA for the First Indication	  	$[* * *]
			
	(E)	  	First Commercial Sale in a Major Country of Europe for the First Indication	  	$[* * *]

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 23 

 (ii) With respect to a Second Indication: 

 

					
	(A)	  	Initiation of dosing of a first patient in a first Phase III Clinical Trial for a Second Indication	  	$[* * *]
			
	(B)	  	Acceptance of filing for Regulatory Approval by the FDA for a Second Indication	  	$[* * *]
			
	(C)	  	First Commercial Sale in the United States for a Second Indication	  	$[* * *]
			
	(D)	  	Acceptance of filing for Regulatory Approval by the EMA for a Second Indication	  	$[* * *]
			
	(E)	  	First Commercial Sale in a Major Country of Europe for a Second Indication	  	$[* * *]

 (iii) With respect to Net Sales of Licensed Products: 

 

					
	(A)	  	The first time that total Net Sales of Licensed Products in the Territory in a Pfizer Year are greater than [* * *] Dollars ($[* * *])	  	$[* * *]
			
	(B)	  	The first time that total Net Sales of Licensed Products in the Territory in a Pfizer Year are greater than [* * *] Dollars ($[* * *])	  	$[* * *]
			
	(C)	  	The first time that total Net Sales of Licensed Products in the Territory in a Pfizer Year are greater than [* * *] Dollars ($[* * *])	  	$[* * *]

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 24 

 (c) Phase III Milestone Advance. In the event that a Phase III
Clinical Trial with respect to a Licensed Product for the First Indication has not been commenced by Pfizer within twelve (12) months after Completion of the Ongoing Clinical Trial, Pfizer will make an advance payment to GMI of fifteen million
dollars ($15,000,000) (the “Phase III Milestone Advance”) against the milestone set forth in Section 4.1(b)(i)(A) with respect to the initiation of a Phase III Clinical Trial for the First Indication; provided, that, the
Phase III Milestone Advance will not be payable if [* * *]; provided further that, if the Phase III Milestone Advance is made, the remainder of the milestone payment set forth in Section 4.1(b)(i)(A), such remaining amount being twenty
million dollars ($20,000,000), shall be payable to GMI by Pfizer within forty-five (45) days of the initiation of dosing of a first patient in a first Phase III Clinical Trial for a First Indication. The Phase III Milestone Advance shall be
payable by Pfizer to GMI within forty-five (45) days after the end of such twelve (12) month period if Pfizer has not provided written notice to GMI of a [* * *] or [* * *], if [* * *]. The payment to GMI under this Section 4.1(c)
shall be non-refundable and shall be creditable only against the milestone payment set forth in Section 4.1(b)(i)(A). 

4.2 Royalties. 
 (a) Royalty Payments. Subject to Sections 4.2(b), (c), and (e), during the Term, Pfizer shall pay to GMI within forty-five (45) days of the end of each calendar quarter royalties on Net Sales
of Licensed Products sold in the corresponding Pfizer Quarter during the Term in the amounts set forth below, which shall be non-creditable and non-refundable: 
  

			
	 (i) Portion of aggregate Net Sales of Licensed Products in all countries of the Territory in a Pfizer Year up to and including $[* * *];
and
	  	[* * *]
		
	 (ii) Portion of aggregate Net Sales of Licensed Products in all countries of the Territory in a Pfizer Year above $[* * *] up to and including
$[* * *]; and
	  	[* * *]
		
	 (iii) Portion of aggregate Net Sales of Licensed Products in all countries of the Territory in a Pfizer Year above $[* * *].
	  	[* * *]

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 25 

 (b) Royalty Period. On a country-by-country and
Licensed Product-by-Licensed Product basis, royalties on each Licensed Product under Section 4.2(a) in each country shall terminate on the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product in such country, after which time there is no
further royalty obligation with respect to such Licensed Product in such country, except that the royalty shall continue after such tenth (10th) anniversary in such country with respect to such Licensed Product sold in such country where in the country where
sold or manufactured such Licensed Product is covered by a Valid Claim of a GMI Patent Right. The termination of royalty payments under this Section 4.2(b) in a country for a Licensed Product shall not terminate the licenses granted to Pfizer
in such country. 
 (c) Third Party Royalties Payable by Pfizer. Subject to clause (d) below, at any
time after the Effective Date, in the event that Pfizer or its Affiliates pays royalties to a Third Party during a Pfizer Quarter for Licensed Product in a country for which royalties are also payable to GMI under this Agreement in such Pfizer
Quarter for sales in such country, and such royalties are due to such Third Party as a result of a Valid Claim of Patent Rights of such Third Party that claims a Compound or use thereof (a “Third Party Royalty”), then [* * *]
percent ([* * *]%) of such Third Party Royalty paid by Pfizer or its Affiliates for sale of such Licensed Product for such Pfizer Quarter in such country may be deducted against [* * *] percent ([* * *]%) of any royalty payments calculated under
Section 4.2(a) with respect to the sale of such Licensed Product in such country for such Pfizer Quarter. 

(d) Third Party Royalties Payable by GMI. GMI shall be solely responsible for making any and all payments that are
due and payable with respect to a Licensed Product under a license agreement between GMI and a Third Party that is in effect as of the Effective Date. 
 (e) Generic Products. In the event that a Generic Product is sold in a country of the Territory in a Pfizer Quarter that in such country or in the country where manufactured is not covered by a
Valid Claim of a GMI Patent Right, then the royalties payable by Pfizer under Section 4.2(a) in such country for the corresponding Licensed Product shall be reduced in the applicable Pfizer Quarter by [* * *] percent ([* * *]%); provided,
however that if in the applicable Pfizer Quarter in the applicable country there is a royalty reduction taken under 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 26 

 
Section 4.2(c), then the royalty reduction under this Section 4.2(e) shall be calculated before the royalty reduction under Section 4.2(c) and in no event shall the royalty
reductions under this Section 4.2(e) and under Section 4.2(c) reduce the royalty on the applicable Licensed Product in the applicable country in the applicable Pfizer Quarter to less than [* * *] percent ([* * *]%) of Net Sales.

 (f) Currency. All payments required under this Article 4 shall be made in U.S. Dollars. For the
purpose of computing the Net Sales of Licensed Products sold in a currency other than U.S. Dollars, such currency shall be converted from local currency to U.S. Dollars in a manner consistent with Pfizer’s normal practices used to prepare its
audited financial statements for external reporting purposes; provided, that such practices use a widely accepted source of published exchange rates. 
 (g) Transfers to Affiliates. No royalties shall be due upon the sale or other transfer of Licensed Product among Pfizer and its Affiliates for resale, or upon the sale or other transfer to a
Sublicensee for resale, but in such cases the royalty shall be due and calculated upon Pfizer’s or its Affiliates or Sublicensees Net Sales to a Third Party. 
 4.3 Royalty Reports and Payments. During the Term, following the First Commercial Sale of a Licensed Product in a country of the Territory, Pfizer shall furnish to GMI a quarterly written report
for each Pfizer Quarter showing for the applicable Pfizer Quarter the gross sales, Net Sales and calculation thereof that breaks-out the applicable deductions permitted in calculating Net Sales on a Licensed Product-by-Licensed Product and
country-by-country basis for all Licensed Products during the applicable Pfizer Quarter, applicable royalty deductions for such Licensed Products, for the applicable Pfizer Quarter, the manner in which conversion to U.S. Dollars was calculated and
the royalties payable under this Agreement for Licensed Products. Reports shall be due on the forty-fifth (45th) day following the close of each calendar quarter. Royalties shown to have accrued by each royalty report shall be due and payable
on the date such royalty report is due; provided if Net Sales in any Pfizer Quarter during a given Pfizer Year are less than zero as a result of permitted reductions in calculating Net Sales under this Agreement, then Pfizer will not be
obligated to pay GMI any royalties for such Pfizer Quarter, and for purposes of calculating royalty payments with respect to the fourth Pfizer Quarter of such 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 27 

 
Pfizer Year, Net Sales for such fourth Pfizer Quarter shall be reduced by the aggregate amount of negative Net Sales in each Pfizer Quarter in which Net Sales are less than zero during the
applicable Pfizer Year that have not been previously deducted from Net Sales. If, as a result of such reduction, the aggregate Net Sales with respect to such fourth Pfizer Quarter are less than zero, then, for purposes of calculating royalty
payments with respect to the first Pfizer Quarter of the next succeeding Pfizer Year, Net Sales for such first Pfizer Quarter shall be reduced by the amount of negative Net Sales in the fourth Pfizer Quarter of the immediately preceding Pfizer Year.
Any adjustment for negative Net Sales described in this Section 4.3 shall be clearly indicated and shown in the applicable royalty reports provided by Pfizer pursuant to this Section 4.3. 

4.4 Royalty Reviews. 
 (a) Access and Review. Upon the written request of GMI and not more than once in each calendar year, and upon at least forty-five (45) days prior written notice, Pfizer shall permit an
independent certified public accounting firm selected by GMI and reasonably acceptable to Pfizer, at GMI’s expense, to have access during normal business hours to such of the records of Pfizer as may be reasonably necessary to verify the
accuracy of the royalty reports and payments hereunder for any or all of the twelve (12) Pfizer Quarters preceding the Pfizer Quarter in which the request is made. The accounting firm shall disclose to GMI and Pfizer only whether the royalty
reports, are correct or incorrect and the amount of any discrepancy. No other information shall be provided to GMI. GMI shall provide Pfizer with a copy of such report within thirty (30) days after receipt thereof. 

(b) Underpayments and Overpayments. If such accounting firm identifies an underpayment of royalties during such
period, Pfizer shall pay GMI the amount of the underpayment within thirty (30) days of the date GMI delivers to Pfizer such accounting firm’s written report so concluding. The fees charged by such accounting firm shall be paid by GMI
unless the underpayment exceeded [* * *] percent ([* * *]%) of the amount owed by Pfizer to GMI for the period audited, in which case, Pfizer shall pay to GMI the fees and costs charged by such accounting firm. If the examination shows an
overpayment of royalties by Pfizer, such amount shall be fully creditable against future royalty payments. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 28 

 (c) Sublicensee Requirements. Pfizer shall include in each sublicense
granted by it pursuant to this Agreement a provision requiring the Sublicensee to make reports to Pfizer, to keep and maintain records of Net Sales made pursuant to such sublicense and to grant access to such records by GMI’s independent
accountant to the same extent required of Pfizer under this Agreement. 
 4.5 Withholding. GMI alone shall be responsible
for paying any and all taxes (other than withholding taxes required to be paid by Pfizer) levied on account of, or measured in whole or in part by reference to, any payments made by Pfizer to GMI under this Agreement. If provision is made in law or
regulation of any country of the Territory for withholding of taxes of any type, levies or other charges with respect to any amounts payable hereunder to GMI, Pfizer (“Withholding Party”) shall promptly pay such tax, levy or charge
for and on behalf of GMI to the proper governmental authority, and shall promptly furnish GMI with a receipt for such payment. The Withholding Party shall have the right to deduct any such tax, levy or charge actually paid from payment due GMI or be
promptly reimbursed by GMI if no further payments are due the Withholding Party. The Withholding Party agrees to assist GMI in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to
time in force and in minimizing the amount required to be so withheld or deducted. The Withholding Party shall apply the reduced rate of withholding, or dispense with withholding, as the case may be, provided that the Withholding Party has received
evidence, in a form satisfactory to the Withholding Party, of GMI’s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least fifteen (15) days prior to the time that the payment
is due. The preceding shall apply mutatis mutandis in the event that any payments shall be made to Pfizer from GMI. 
 4.6
Interest for Late Payment. All payments under this Agreement shall bear interest from the fifteenth (15th) day after the date due until paid at a rate equal to [* * *] rate in effect on the date that payment was due, as published by
The Financial Times. For purposes of this Section 4.6, the due date for any overpayment or underpayment determined pursuant to any audit, review, investigation or adjustment hereunder shall be the date specified in the relevant provision
in this Agreement for payment of such overpayment or underpayment after completion of such audit, review, investigation or adjustment and no interest shall be retroactively payable back to the original due date for the payments underlying any such
overpayment or underpayment. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 29 

 Article 5 INTELLECTUAL PROPERTY RIGHTS 

5.1 Prosecution. Promptly after the Effective Date and thereafter, GMI shall provide or cause to be provided to Pfizer or its
counsel a copy of the patent office files with respect to filing, prosecution and maintenance of the GMI Patent Rights licensed to Pfizer under this Agreement. [* * *] 
 Neither Party shall have liability to the other Party for any act, omission, or default or neglect of outside counsel selected pursuant to this Section 5.1 with respect to filing, prosecuting or
maintaining of GMI Patent Rights pursuant to this Section 5.1. 
 5.2 Notices of Infringement. 

(a) Each Party shall give the other Party notice of any actual or suspected infringement of GMI Patent Rights in the
Territory that comes to the Party’s attention. The notice requirements of this Section 5.2(a) shall be limited to those circumstances where the actual or suspected infringement, is with respect to the manufacture, use, sale, import or
offering for sale of Licensed Product in the Field. 
 (b) With respect to the alleged infringement by a Third
Party of GMI Patent Rights by making, using, selling, importing or offering for sale a Licensed Product in the Field in the Territory (a “Product Infringement”), as between GMI and Pfizer, Pfizer will have the first right (but not
the obligation) to bring any infringement action or proceeding against such Product Infringement, at the cost and expense of Pfizer, by counsel of its own choice. GMI will have the right, at its own cost and expense, to be represented in any such
action by counsel of its own choice, but Pfizer shall control such infringement action. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 30 

 (c) For any action pursuant to Section 5.2(b) to terminate any Product
Infringement of GMI Patent Rights that Pfizer is entitled to bring, in the event that Pfizer is unable to initiate or prosecute such action solely in its own name, GMI will join such action voluntarily and will execute all documents necessary for
Pfizer to initiate litigation to prosecute and maintain such action. In connection with any action, Pfizer and GMI will cooperate fully and will provide each other with any information or assistance that the other may reasonably request, at the
expense of the enforcing Party. Pfizer will have the right to control such action, including the settlement thereof, provided, however, that Pfizer shall not settle or compromise any claim or proceeding that adversely affects the scope, validity or
enforceability of any GMI Patent Right licensed to Pfizer unless agreed to in writing by both Parties, which consent shall not be unreasonably withheld. Any damages or other monetary awards recovered pursuant to any suit, proceeding or other legal
action taken under this Section 5.2 will be allocated first to the costs and expenses of Pfizer, and second to the costs and expenses (if any) of GMI that were not otherwise reimbursed, with any remaining amounts (if any) to be allocated to
Pfizer and such remaining amount shall be Net Sales subject to royalty under this Agreement. 
 (d) Each Party
shall inform the other Party of any certification regarding any GMI Patent Rights in the United States it has received pursuant to either 21 U.S.C. §§355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) or its successor provisions or any similar
provisions in the Territory and shall provide the other Party with a copy of such certification within ten (10) Business Days of receipt. Pfizer’s rights with respect to the initiation and prosecution of any legal action as a result of
such certification or any recovery obtained as a result of such legal action shall be as defined in Section 5.2(b), and (c). 
 (e) In the event that a Third Party files a declaratory judgment action or any other type of action or proceeding with respect to any GMI Patent Rights against either Party or both Parties in the
Territory, such Party shall provide written notice thereof to the other Party within ten (10) Business Days thereafter. Pfizer shall have the first right within its sole discretion, but not the obligation, to control the defense thereof with
attorneys selected by Pfizer, at the cost and expense of Pfizer. Pfizer shall not settle or compromise such an action or proceeding in a manner that materially adversely affects the scope, validity or enforceability of any GMI Patent Rights in the
Territory without the written consent of GMI, which consent shall not be withheld unreasonably. If Pfizer is unable to defend such action solely in its own name, GMI shall join such action voluntarily and shall execute and cause its Affiliates and
sublicensees to execute all documents necessary for Pfizer to defend such action. Pfizer shall keep GMI reasonably informed of the course of such action. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 31 

 5.3 Extensions. The Parties shall discuss with each other obtaining any patent term
extension, such as extension under 35 U.S.C. § 156, patent term restoration or supplemental protection certificates or their equivalents in any country in the Territory with respect to any patent term extension regarding GMI Patent Rights, in
each case that contain a claim that would be infringed by manufacture, use, importation, offer for sale or sale of a Licensed Product in the Field. Pfizer shall have the right to make the election in its sole discretion with respect to GMI Patent
Rights and GMI shall abide by such election with respect to GMI Patent Rights and, if requested by Pfizer, cooperate with Pfizer to supply information and assistance useful in obtaining patent term extension. 

Article 6 CONFIDENTIALITY; PUBLICATION 
 6.1 Confidential Information. 
 (a) All information
including Know-How disclosed by one Party to the other Party hereunder shall be considered confidential information of the disclosing Party (“Confidential Information”). Subject to Sections 6.1(b) and (c), each Party agrees that
(i) during the Term and for [* * *] ([* * *]) years after the Term it will keep confidential, and will cause its Affiliates to keep confidential, all of the other Party’s Confidential Information, (ii) each Party and its respective
Affiliates shall use any Confidential Information only as expressly permitted in this Agreement; (iii) it shall take such action, and to cause its Affiliates to take such action, to preserve the confidentiality of the other Party’s
Confidential Information as it would customarily take to preserve the confidentiality of its own similar types of confidential information, but in no event less than reasonable care and (iv) no Party shall disclose such Confidential Information
to any Third Parties under any circumstance without the prior written consent of the other Party, except to the extent that such Confidential Information: 
 (i) is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s business records; 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 32 

 (ii) is or becomes part of the public domain through no fault of the
receiving Party; 
 (iii) is subsequently disclosed to the receiving Party by a Third Party who may lawfully do
so and is not under an obligation of confidentiality to the disclosing Party; or 
 (iv) is developed by the
receiving Party independently of information received from the disclosing Party, as documented by the receiving Party’s business records. 
 (b) Notwithstanding the obligations in Section 6.1(a), Pfizer has the right to use and permit a Third Party to use the Confidential Information of GMI that is licensed to Pfizer pursuant to the
license and rights granted to Pfizer under this Agreement. In addition, Pfizer may disclose the Confidential Information of GMI, if such disclosure: (i) is made by Pfizer, its Affiliates or Sublicensees to a Regulatory Authority in order to
gain or maintain approval to conduct clinical trials of Licensed Product or to market Licensed Product in the Territory, in which case Pfizer, its Affiliate or Sublicensee shall request confidential treatment thereof to the extent permitted by
applicable law, rule or regulation; (ii) is under an obligation of confidentiality and is made by Pfizer to Sublicensees, Affiliates, agents, consultants, or other Third Parties, in each case for the research, development, manufacturing or
commercialization of Licensed Product in the Field and/or is made by Pfizer in connection with a permitted assignment of this Agreement, or a licensing transaction related to Licensed Product in the Field, which obligation of confidentiality
provides that the Third Party agrees to be bound by confidentiality and non-use obligations substantially similar to those contained in Article 6 of this Agreement, and that such information will only be used for the applicable purpose;
(iii) is in connection with filing or prosecuting GMI Patent Rights or trademark rights by Pfizer as permitted by this Agreement but only after the consent of GMI which shall not be unreasonably withheld, (iv) is in connection with
prosecuting or defending litigation by Pfizer as permitted by this Agreement, (v) is in connection with posting results of and other information about clinical trials to clincialtrials.gov or PhRMA websites, and (vi) is necessary or
desirable by Pfizer in order to enforce its rights under this Agreement; provided that in the case of any such disclosure pursuant to subparts (iv) and (vi), to the extent that Pfizer is not prohibited by applicable law

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 33 

 
from doing so, Pfizer shall promptly inform GMI of the proposed disclosure in order to provide GMI an opportunity to challenge or limit the disclosure obligations. GMI may disclose information
received from Pfizer under this Agreement that is Confidential Information of Pfizer (i) to Regulatory Authorities in order to respond to inquiries, requests or investigations relating to this Agreement; (ii) to the extent necessary or
desirable in order to enforce its rights under this Agreement; (iii) in connection with an assignment of this Agreement or (iv) in connection with a potential or completed loan, financing or investment in GMI or Change of Control of GMI,
provided that in the case of any such disclosure pursuant to subpart (ii), to the extent that GMI is not prohibited by applicable law from doing so, GMI shall promptly inform Pfizer of the proposed disclosure in order to provide Pfizer an
opportunity to challenge or limit the disclosure obligations; and provided further that such disclosure by GMI under subparts (iii) and (iv) is under confidentiality and non-use provisions substantially similar to those of GMI under
Article 6 of this Agreement and that such information will only be used for the purposes of such transaction; and provided, further, that GMI may disclose the following information in the normal conduct of its business: (A) the amount of the
payment received pursuant to Section 4.1(a), (B) the total amounts of all payments potentially payable under Section 4.1 (but not any individual amount or subtotal amount thereunder), and (C) the fact that Pfizer may pay
“tiered, double-digit” royalties to GMI hereunder; provided, however, that any press release regarding this Agreement or events occurring hereunder shall in any event be subject to Section 6.4. 

(c) If a Party is required by law or regulation (including, without limitation, regulations of the Securities and
Exchange Commission and the U.S. Food and Drug Administration) or judicial or administrative process to disclose Confidential Information that is subject to the non-disclosure provisions of this Section 6.1, to the extent that such Party is not
prohibited by applicable law from doing so, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential
Information that is disclosed by law or regulation or judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Section 6.1, and the Party disclosing Confidential Information
pursuant to law or court order shall, except where impracticable, take all steps reasonably necessary, including without limitation obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential
Information. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 34 

 6.2 Publication. 

(a) Without limiting any rights or obligations of the Parties under Sections 6.1, 6.2(b), 6.2(c) and 6.3, during the
Term, each Party shall submit to the other Party (the “Non-Disclosing Party”) for review and approval any proposed academic, scientific and medical publication or public presentation which contains the Non-Disclosing Party’s
Confidential Information. In addition, GMI shall submit to Pfizer for review and approval any proposed publication or public presentation relating to the Compounds, Licensed Products or any pre-clinical or clinical studies conducted by or on behalf
of GMI with respect thereto. In both instances, such review and approval will be conducted for the purposes of preserving the value of each Party’s Patent Rights and Know-How, the rights granted to Pfizer hereunder and determining whether any
portion of the proposed publication or presentation containing the Non-Disclosing Party’s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required to be submitted hereunder
shall be submitted to the Non-Disclosing Party no later than thirty (30) days before submission for publication or presentation. The Non-Disclosing Party shall provide its comments with respect to such publications and presentations within
fifteen (15) Business Days after its receipt of such written copy from the other Party. The review period may be extended for an additional thirty (30) days in the event the Non-Disclosing Party can demonstrate reasonable need for such
extension including for the preparation and filing of patent applications. GMI and Pfizer will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any
publication. For the sake of clarity, (1) Pfizer shall have the right, subject to GMI’s rights of review as set forth above, to include in its academic, scientific and medical publications and public presentations any pre-clinical and
clinical data and results relating to any Licensed Product or Compound, including without limitation any such data and results provided to Pfizer under Section 2.3 and data and results of the Ongoing Clinical Study, (2) subject to
Section 6.2(b) GMI shall not include in its academic, scientific and medical publications and public presentations any pre-clinical and clinical data and results relating to any 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 35 

 
Licensed Product or Compound, including without limitation any such data and results provided to Pfizer under 2.3 and data and results of the Ongoing Clinical Study, without Pfizer’s prior
written consent, such consent not to be unreasonably withheld, and (3) Pfizer’s obligation to submit any publication to GMI for review and approval under this Section 6.2(a) shall not apply to any publication which does not contain
GMI’s Confidential Information. 
 (b) Pfizer understands that there are rights to publish under existing
agreements between GMI and Third Parties which are subject to certain restrictions, and nothing in this Section 6.2 shall limit such publication rights pursuant to such agreements; provided, however that GMI, to the extent practicable in light
of such restrictions, shall provide Pfizer with the opportunity to review and comment on such publications as set forth above. 
 (c) Except as permitted by Section 6.1, Pfizer shall not have the right to publish or disclose Confidential Information of GMI pursuant to Section 6.2(a) that is not pre-clinical data and/or
clinical data or results without the written consent of GMI. 
 6.3 Disclosure of the Agreement. 

(a) Neither Party shall disclose the terms of this Agreement, except either Party shall be permitted to disclose the
terms of this Agreement to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with applicable laws, rules or regulations, including without limitation the rules and regulations promulgated by the United
States Securities and Exchange Commission (“SEC”) or any other governmental agency. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 6.3(a), the Parties shall
allow at least fifteen (15) days for the other Party to review the disclosure of the terms of this Agreement for which confidential treatment will be sought in making any such disclosure. If a Party wishes to disclose this Agreement or any of
the terms hereof in accordance with this Section 6.3(a), such Party agrees, at its own expense, to the extent available to seek confidential treatment of the portions of this Agreement or such terms as may be reasonably requested by the other
Party, provided that the disclosing Party shall always be entitled to make such disclosure even if such treatment is or cannot be obtained from the governmental agency or authority. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 36 

 (b) Either Party may also disclose the terms of this Agreement in confidence
to (i) its Affiliates, attorneys, consultants and advisors, (ii) in connection with a potential Change of Control, to potential acquirors (and their respective professional advisors), (iii) as a part of their due diligence
investigations, to or existing and potential investors or lenders (and their respective professional advisors) of such Party, or (iv) to permitted assignees, in each of the foregoing cases under an agreement to keep the terms of this Agreement
confidential under terms of confidentiality and non-use substantially similar to the terms contained in Article 6 of this Agreement and to use such confidential information solely for the purpose permitted pursuant to this Section 6.3(b).
Notwithstanding the foregoing, if GMI after exerting reasonable efforts cannot obtain an agreement of confidentiality as to this Agreement in connection with a financing and/or public offering, GMI shall have the right to disclose this Agreement
and/or the terms thereof without an obligation of confidentiality; provided that GMI provides written notice to Pfizer at least five (5) Business Days prior to such disclosure and [* * *] until in GMI’s reasonable judgment such
disclosure should be made by GMI. 
 6.4 Press Releases. The public announcement of the execution of this Agreement is
set forth Schedule 6.4 attached hereto and GMI shall be permitted to distribute such public announcement upon execution hereof by both Parties. Subject to the foregoing provisions of this Article 6, GMI or Pfizer may issue subsequent press releases
with respect to events that occur pursuant to this Agreement with the consent of the other Party, which consent shall not be unreasonably withheld; provided that each Party shall allow the other Party [* * *] days to review the proposed press
release prior to providing its consent for the issuance of the press release. 
 Article 7 REPRESENTATIONS AND WARRANTIES;

 ADDITIONAL COVENANTS 
 7.1 Representations and Warranties by GMI. As of the Effective Date, GMI represents and warrants to Pfizer that: 

(a) it has the right to grant the rights and licenses granted to Pfizer under this Agreement, and pursuant to this
Agreement, Pfizer has been granted such rights and licenses; 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 37 

 (b) to its Knowledge, the granted patents encompassed within the GMI Patent
Rights of Exhibit A are valid and enforceable, and no Third Party has challenged or threatened to assert a challenge to the validity or enforceability of the GMI Patent Rights of Exhibit A (including by way of example through the institution or
written threat of institution of interference, nullity or similar invalidity proceedings before the United Stated Patent and Trademark Office or any analogous foreign entity); 

(c) to its Knowledge, the manufacture, use, sale, offer to sell, importation or exploitation by GMI or Pfizer (or their
respective Affiliates) of any Licensed Product or Compound as formulated and manufactured as of the Effective Date does not infringe any issued patent of a third party; 

(d) Exhibit A contains a complete and correct list of all GMI Patent Rights; 

(e) it is the sole owner of all the GMI Patent Rights, free of any lien, encumbrance, charge, security interest, mortgage
or other similar restriction. No Person (including any Affiliate of GMI) has any right, interest or claim in or to, and neither GMI nor any of its Affiliates has entered into any agreement granting any right, interest or claim in or to, any GMI
Patent Rights or GMI Know-How, except for the rights granted to Third-Party service providers or investigators solely to conduct the On Going Clinical Trial and the other studies as listed on Schedule 2.1 (which rights do not include the right to
practice or use the GMI Patent Rights or GMI Know-How to manufacture, commercially distribute or sell the Compound and/or Licensed Product). All inventors of the GMI Patent Rights have assigned to GMI their rights in such GMI Patent Rights and all
such assignments are valid and enforceable; 
 (f) it has complied in all material respects with all applicable
Laws in connection with the filing, prosecution and maintenance of the GMI Patent Rights of Exhibit A; 
 (g)
there is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the Knowledge of GMI,
threatened against GMI, any of its Affiliates or, to the Knowledge of GMI, any Third Party, in each case in connection with the GMI Patent Rights of Exhibit A, GMI Know-How, the Compounds or the Licensed Products or relating to the transactions
contemplated by this Agreement; 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 38 

 (h) all necessary consents, approvals and authorizations of all government
authorities and other entities or persons required to be obtained by GMI as of the Effective Date in connection with the execution, delivery and performance of this Agreement and the granting of the rights and licenses granted under this Agreement
have been obtained; 
 (i) no Person, including but not limited to any holder of GMI’s Series A-1 Preferred
Stock or any investor in any other round of financing of GMI, has any option or other right to negotiate any license, option, collaboration, joint venture, sale or any similar transaction with GMI with respect to the Compound or Licensed Product in
the Territory except as listed in Schedule 7.1; provided that, as of the Effective Date, GMI has the right to grant the license granted to Pfizer under this Agreement free and clear of any such option and/or other right of any Person set forth in
Schedule 7.1 and after the Effective Date any Person set forth in Schedule 7.1 has no further option or right to negotiate any license, option, collaboration, joint venture, sale or any similar transaction with GMI with respect to the Compound or
Licensed Product in the Territory; 
 (j) to its Knowledge, GMI has not used in any capacity the services of any
person or entity debarred under Section 306 of the Federal Food, Drug and Cosmetic Act in connection with the research, development or manufacture of Product; 

(k) None of the rights of GMI or its Affiliates under the GMI Patent Rights of Exhibit A were developed with federal
funding from the United States government or any other Governmental Authority; 
 (l) None of the GMI Patent
Rights of Exhibit A have been licensed from a Third Party; 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 39 

 (m) GMI has heretofore disclosed to Pfizer all material scientific and
technical information and all information relating to safety and all material information relating to efficacy, in each case with respect to any Compound or Licensed Product, and in each case that is known to GMI; 

(n) GMI has heretofore disclosed to Pfizer all material correspondence and contact information between GMI and the FDA
and any other Regulatory Authorities regarding the Compounds or the Licensed Products; 
 (o) it is a
corporation duly organized, validly existing and in good standing under the laws of Delaware and has the right, power and authority to enter into this Agreement and to make the promises set forth in this Agreement; 

(p) it has taken all necessary action on its part, including but not limited to action required by Law, its certificate
of incorporation, by-laws or other organizational documents or any agreement to which it is party or to which it may be subject, required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;

 (q) it has duly executed and delivered this Agreement and, assuming due delivery and execution by Pfizer,
this Agreement constitutes a legal, valid and binding obligation of GMI, enforceable against GMI in accordance with its terms; except to the extent that such enforceability may be limited by bankruptcy, insolvency, or other similar laws relating to
creditors’ rights generally; and 
 (r) the execution, delivery and performance of this Agreement do not
conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor to its Knowledge, violate any Law or regulation of any court, governmental body or administrative or other agency having
jurisdiction over it. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 40 

 7.2 Representations and Warranties by Pfizer. As of the Effective Date, Pfizer
represents, and warrants to GMI that: 
 (a) it is a corporation duly organized, validly existing and in good
standing under the laws of Delaware and has the right, power and authority to enter into this Agreement and to make the promises set forth in this Agreement; 
 (b) it has taken all necessary action on its part, including but not limited to action required by Law, its certificate of incorporation, by-laws or other organizational documents or any agreement to
which it is party or to which it may be subject, required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; 

(c) it has duly executed and delivered the Agreement, and assuming due delivery and execution by GMI this Agreement
constitutes a legal, valid and binding obligation of Pfizer, enforceable against Pfizer in accordance with its terms; except to the extent that such enforceability may be limited by bankruptcy, insolvency, or other similar laws relating to
creditors’ rights generally; and 
 (d) the execution, delivery and performance of this Agreement do not
conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor to its Knowledge, violate any Law or regulation of any court, governmental body or administrative or other agency having
jurisdiction over it. 
 7.3 LIMITATIONS. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER GMI NOR
PFIZER MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT AND EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS ARTICLE 7, EACH PARTY HEREBY EXPRESSLY DISCLAIMS
ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND ANY WARRANTY OR REPRESENTATION REGARDING CLINICAL EFFECTIVENESS OF LICENSED PRODUCT OR THAT ANY PATENT APPLICATION WILL BE GRANTED
OR THAT A LICENSED PRODUCT CAN BE SUCCESSFULLY DEVELOPED OR COMMERCIALIZED. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 41 

 7.4 Additional Covenants. 

(a) Compliance with Laws. Each of GMI and Pfizer shall conduct, and shall use reasonable efforts to cause its
Affiliates to conduct, all its activities contemplated under this Agreement in accordance with all applicable Laws of the country in which such activities are conducted. 

(b) Reasonable Access. From and after the Effective Date, GMI shall, upon reasonable notice from Pfizer, provide
Pfizer and its agents and representatives with reasonable access, during regular business hours, to (i) all information concerning Compounds, Licensed Products and/or GMI Patent Rights, and (ii) all employees of GMI who possess any
information described in clause (i) of this Section 7.4(b), in each case to the extent reasonably necessary to allow Pfizer to exercise its rights or carry out its obligations under this Agreement. 

7.5 Exclusion of Certain Damages. Except with respect to an obligation of either Party to indemnify the other hereunder, neither
Party shall be liable to the other for consequential, incidental, indirect or punitive damages arising from the performance or nonperformance of such Party under this Agreement whether such claim is based on contract, tort (including negligence) or
otherwise, even if an authorized representative of such Party is advised of the possibility or likelihood of same. 
 Article
8 INDEMNITY 
 8.1 Indemnification by Pfizer. Pfizer agrees to defend, indemnify and hold harmless GMI and its
Affiliates and their respective directors, officers and employees (individually and collectively, the “GMI Indemnitee(s)”) from and against any and all costs, expenses, claims, losses, liabilities, damages, fines, royalties,
governmental penalties or punitive damages, deficiencies, interest, settlement amounts, awards, and judgments, including any and all reasonable, out-of-pocket costs and expenses properly incurred as a result of a claim (including reasonable,
out-of-pocket attorneys’ fees and all other expenses reasonably incurred in investigating, preparing or defending any litigation or proceeding, commenced or threatened), in each case, net of any insurance recovery received as a result of such
cost (collectively, “Losses”) 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 42 

 
resulting from any claims, demands, actions or other proceedings by any Third Party to the extent arising from (a) the research, development, testing, manufacture, use, handling, storage,
commercialization, marketing, sale or other disposition of Licensed Products by or on behalf of Pfizer or any of its Affiliates or Sublicensees in the Territory during the Term or thereafter pursuant to Section 9.1 or 9.10 of this Agreement, or
(b) the use of Licensed Products that were sold or distributed by or on behalf of Pfizer or any of its Affiliates or Sublicensees during the Term or thereafter pursuant to Section 9.1 or 9.10 of this Agreement, or (c) the negligence,
recklessness or intentional misconduct or unlawful act of Pfizer or its Affiliates or Sublicensees in exercising rights and/or carrying out activities under this Agreement or the licenses granted under this Agreement, or (d) a breach of a
representation, warranty or covenant made by Pfizer under this Agreement. 
 8.2 Indemnification by GMI. GMI agrees to
defend, indemnify and hold harmless Pfizer, and its Affiliates, and their directors, officers and employees (individually and collectively, the “Pfizer Indemnitee(s)”) from and against all Losses resulting from any claims, demands,
actions or other proceedings by any Third Party to the extent arising from (a) the research, development or commercialization of the Compounds or Licensed Products by or on behalf of GMI or its Affiliates or licensees prior to the Effective
Date or subsequent to the Effective Date and prior to completion of the Ongoing Clinical Trial, (b) the research, development or commercialization after termination of this Agreement of any Compounds or Licensed Product by or on behalf of GMI
or its Affiliates, where such Compound or Licensed Product was researched, developed or commercialized pursuant to the license granted to GMI under Section 9.5 or with the use of any of the information, documents or other materials transferred
to GMI pursuant to Section 9.5(e), (c) the use of Licensed Products that were sold or distributed by or on behalf of GMI or any of its Affiliates prior to the Effective Date, or subsequent to the Effective Date and prior to completion of
the Ongoing Clinical Trial, (d) the use of Licensed Products sold or distributed by or on behalf of GMI or any of its Affiliates after termination of this Agreement, where such Compound or Licensed Product was researched, developed or
commercialized pursuant to the license granted to GMI under Section 9.5 or with the use of any of the information, documents or other materials transferred to GMI pursuant to 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 43 

 
Section 9.5(e), or (e) the negligence, recklessness or intentional misconduct or unlawful act of GMI or its Affiliate in exercising rights and/or carrying out activities under this
Agreement or pursuant to the rights granted by Pfizer to GMI pursuant to Section 9.6 of this Agreement, or (d) a breach of representation, warranty or covenant made by GMI under this Agreement. 

8.3 Indemnitee/Indemnifying Party. Each of the Pfizer Indemnitee and GMI Indemnitee shall be an “Indemnitee” for
the purpose of this Article 8, and the Party that is obligated to indemnify the Indemnitee under Section 8.1 or Section 8.2 shall be the “Indemnifying Party.” 

8.4 Defense Procedures; Procedures for Third Party Claims. In the event that any Third Party (in no event to include any Affiliate
of any of the parties) asserts a claim with respect to any matter for which an Indemnitee is entitled to indemnification hereunder (a “Third Party Claim”), then the Indemnitee shall promptly notify the Indemnifying Party thereof;
provided, however, that no delay on the part of the Indemnitee in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is
prejudiced thereby. 
 (a) The Indemnifying Party shall have the right, exercisable by notice to the Indemnitee
within ten (10) Business Days after receipt of notice from the Indemnitee of the commencement of or assertion of any Third Party Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the
Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnitee; provided that (i) the Indemnifying Party has
sufficient financial resources, in the reasonable judgment of the Indemnitee, to satisfy the amount of any adverse monetary judgment that is sought, (ii) the Third Party Claim seeks solely monetary damages and (iii) the Indemnifying Party
expressly agrees in writing that as between the Indemnifying Party and the Indemnitee, the Indemnifying Party shall be solely obligated to satisfy and discharge the Third Party Claim in full (the conditions set forth in clauses (i), (ii) and
(iii) above are collectively referred to as the “Litigation Conditions”). 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 44 

 (b) Within ten (10) Business Days after the Indemnifying Party has
given notice to the Indemnitee of its exercise of its right to defend a Third Party Claim, the Indemnitee shall give notice to the Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnitee reasonably so
objects, the Indemnitee shall continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until such time as such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn, the Indemnifying
Party shall be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnitee. During such time as the Indemnifying Party is
controlling the defense of such Third Party Claim, the Indemnitee shall cooperate, and shall cause its Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of the Third Party Claim, including by
furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or appeals as may reasonably be requested by the Indemnifying Party. In the event that the Indemnifying Party does not satisfy
the Litigation Conditions or does not notify the Indemnitee of the Indemnifying Party’s intent to defend any Third Party Claim within ten (10) Business Days after notice thereof, the Indemnitee may (without further notice to the
Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party’s expense (including reasonable, out-of-pocket attorneys’ fees and costs and expenses of enforcement or defense). The Indemnifying
Party or the Indemnitee, as the case may be, shall have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense
of any Third Party Claim that the other Party is defending as provided in this Agreement. 
 (c) The
Indemnifying Party shall not, without the prior consent of the Indemnitee, enter into any compromise or settlement that commits the Indemnitee to take, or to forbear to take, any action. The Indemnitee shall have the sole and exclusive right to
settle any Third Party Claim, on such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but shall not have the right to settle such Third Party Claim to the
extent such Third Party Claim involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnitee shall not make any admission of liability in respect of any Third Party Claim
without the prior consent of the other party, and the Indemnitee shall use reasonable efforts to mitigate losses arising from the Third Party Claim. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 45 

 (d) Notwithstanding the foregoing, the Indemnitee may be represented by
separate counsel of its choosing at the cost and expense of the Indemnifying Party if a conflict of interest exists such that the counsel selected by the Indemnifying Party cannot simultaneously represent the Indemnitee. 

8.5 LIMITATIONS. IN NO EVENT SHALL ANY PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE UNDER THIS AGREEMENT FOR SPECIAL,
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, WITH RESPECT TO ACTIVITIES UNDER OR IN CONNECTION WITH THIS AGREEMENT SUFFERED BY PFIZER, GMI OR ANY OF THEIR RESPECTIVE
REPRESENTATIVES, EXCEPT (A) FOR PURPOSES OF INDEMNIFICATION PURSUANT TO THIS ARTICLE 8, OR (B) IN THE EVENT OF AN INTENTIONAL OR WILLFUL BREACH IN BAD FAITH OF ANY REPRESENTATION, WARRANTY, COVENANT OR AGREEMENT BY GMI OR PFIZER (AS THE
CASE MAY BE) CONTAINED IN THIS AGREEMENT; PROVIDED THAT THIS SECTION SHALL NOT RELIEVE EITHER PARTY FROM ITS PAYMENT OBLIGATIONS UNDER THIS AGREEMENT. 
 Article 9 TERM AND TERMINATION 
 9.1 Term. The term of this
Agreement shall be effective as of the Effective Date and shall continue in effect until the earlier of (i) termination of this Agreement under this Article 9 or (ii) expiration of all royalty payment obligations hereunder (the
“Term”). Upon expiration (but not termination of this Agreement), the licenses granted to Pfizer under Section 2.1 of this Agreement shall become a fully paid-up, irrevocable, royalty-free, perpetual license. 

9.2 Termination at Will. Notwithstanding anything contained herein to the contrary, Pfizer shall have the right to terminate this
Agreement in its sole discretion in its entirety by giving [* * *] ([* * *]) days prior written notice to GMI. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 46 

 9.3 Termination for Breach. In addition to the termination provision of
Section 9.2, this Agreement may be terminated at any time during the Term by a Party if the other Party materially breaches or materially defaults in the performance or observance of an obligation under this Agreement. A written notice of such
breach shall be sent by a Party to the other Party and the written notice shall specify the breach, and if such written notice has been given and the applicable Party has not cured a payment breach by making a payment within [* * *] ([* * *]) days
of the written notice or has not cured a breach that is not a payment breach within [* * *] ([* * *]) days of the written notice, then by prompt further written notice to the breaching party after the expiration of the applicable period
without cure, the notifying Party may terminate this Agreement. For the avoidance of doubt, material breaches that may permit termination under this Section 9.3 by the non-breaching Party include, without limitation, uncured material failures
to make payments when due and uncured material breaches under Section 2.1, 2.3, 3.1(a), 3.2(a), Article 6, Article 7, Article 8 and Article 10 of this Agreement. 
 9.4 Termination for Insolvency. Each Party shall have the right to terminate this Agreement upon written notice (a) if voluntary or involuntary proceedings by or against the other Party are
instituted in bankruptcy or under any insolvency law, or a receiver or custodian is appointed for the other Party, or proceedings are instituted by or against the other Party for corporate reorganization or the dissolution or liquidation of the
other Party under the U.S. Bankruptcy Code, which proceedings, if involuntary, shall not have been dismissed within [* * *] ([* * *]) days after the date of filing, or if the other Party makes an assignment for the benefit of creditors, or
substantially all of the assets of the other Party are seized or attached and not released within [* * *] ([* * *]) days thereafter, or (b) upon the voluntary liquidation, dissolution, winding up or cessation of business by the other Party
other than in connection with a permitted assignment of this Agreement. 
 9.5 Consequences of Termination. Upon
(i) termination of this Agreement by GMI or (ii) termination of this Agreement by Pfizer in accordance with Section 9.2: 
 (a) Except as expressly set forth herein, including in Section 9.13, all rights and licenses granted to Pfizer under this Agreement shall terminate and neither Pfizer nor its Affiliates shall
research, develop, market, sell or otherwise commercialize a Licensed Product and/or Compound. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 47 

 (b) Subject to Section 9.5(c), upon written notice from GMI, Pfizer
agrees to grant to GMI as of the date of such termination of this Agreement a non-exclusive license, with the right to sublicense, to research, develop, make, have made, use, export, import, offer to sell, sell and commercialize Compounds and
Licensed Products in the Reference Forms, in the Field in the Territory under Pfizer Patent Rights and Pfizer Know-How, and upon such written notice such license shall be automatically granted without any further action by Pfizer or GMI. 

(c) In the event that Pfizer Patent Rights and/or Pfizer Know-How are licensed to Pfizer by a Third Party, and such
Pfizer Patent Rights and/or Pfizer Know-How are reasonably required by GMI to make, have made, use, sell, offer to sell, import, export, research, develop and/or commercialize Compounds and/or Licensed Products and Pfizer has the right to grant a
sublicense thereunder to GMI when this Agreement is terminated, Pfizer shall notify GMI of such Pfizer Patent Rights and Pfizer Know-How, and then at the request of GMI, Pfizer shall grant to GMI such a sublicense to the fullest extent permitted
under the license under which the sublicense is granted and subject to the terms, conditions and requirements thereof to make, have made, use, sell, offer to sell, import, export, research, develop and/or commercialize Compounds and Licensed
Products to the same extent and as set forth in Section 9.5(b). Such sublicense shall be granted in a separate agreement without additional consideration to Pfizer, provided that GMI [* * *]. 

(d) In the event that at the date of such termination Pfizer or its Affiliate or their supplier is responsible for
manufacturing a Licensed Product and/or Compounds for the purposes of conducting clinical trials and/or for commercializing a Licensed Product in the Territory, then upon GMI’s written request until the earlier of (A) the date that GMI
obtains an alternative supply thereof or (B) (i) with respect to the supply of the Licensed Product and/or Compounds prior to Regulatory Approval in a country in the Territory, [* * *], and (ii) with respect to the supply of the
Licensed Product and/or Compounds for commercial sale after Regulatory Approval (and Pricing Approval, if applicable), [* * *], at GMI’s option, Pfizer shall supply such Licensed Product and Compounds to GMI at Pfizer’s or its
Affiliate’s cost for such 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 48 

 
Licensed Product and/or Compounds (and in the case where Pfizer or its Affiliate manufactures such Licensed Product and/or Compounds, such cost shall be [* * *] percent ([* * *]%) of Pfizer’
or its Affiliate’s fully-burdened manufacturing cost for such Licensed Product and/or Compounds); provided however, if there are restrictions in an agreement between Pfizer or an Affiliate of Pfizer and a Third Party governing the
manufacture or supply of such Licensed Product and/or any such Compound that would limit the amount of such Licensed Product and/or any such Compound that could be supplied to GMI or that would preclude the period from being up until [* * *], then
the limits in such agreement as to the amount of such Licensed Product and/or any such Compound that could be supplied shall govern and such period shall be up to as long a time as permitted under such agreement, and further provided that if Pfizer
or its Affiliate is manufacturing the Compound and/or Licensed Product, Pfizer shall not be obligated to manufacture and supply such Compound and/or Licensed Product in amounts that exceed the amounts of such Compound and/or Licensed Product which
were being manufactured by Pfizer or its Affiliate as of the date of termination. Notwithstanding the foregoing, in the event that Pfizer is obtaining supplies from a Third Party, the Parties shall meet and discuss in good faith whether it is
possible to assign the Third Party agreements to GMI. 
 (e) Upon the request of GMI, Pfizer shall transfer to
GMI, at the cost and expense of Pfizer, clinical data from any Additional Phase II Clinical Trial and any Phase III Clinical Trial of a Licensed Product, all marketing authorizations, INDs and other regulatory filings and Regulatory Approvals in the
Territory for any Licensed Product that is being developed and/or commercialized by Pfizer or its Affiliates as of the date of such termination. For the avoidance of doubt, Pfizer will transfer ownership of the items described in the preceding
sentence, together with the privileges, benefits and obligations associated with the ownership of such items. In the event that in any country such transfer is not legally possible, Pfizer shall (and shall cause its Affiliates) to take all
reasonable actions that are permitted by the applicable Regulatory Authority to permit GMI to also have the benefit of the relevant marketing authorizations, INDs and other regulatory filings and Regulatory Approvals in the applicable country that
exist at the time of termination for any such Licensed Product in the applicable country, including allowing GMI to cross-reference data and information on file with the 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 49 

 
Regulatory Authority in the applicable country, and to this end, Pfizer itself consents to and shall cause its Affiliates to consent to such Regulatory Authority cross-referencing to the data and
information on file with such Regulatory Authority to the extent that it exists at the time of such termination as may be necessary to facilitate the granting of permitted second marketing authorizations, INDs, regulatory filings and Regulatory
Approvals in applicable country to GMI. In addition, upon GMI’s request, Pfizer will provide GMI for use by GMI with (a) copies of human clinical experience databases as updated following completion or termination of any ongoing trials,
(b) copies of completed and final clinical study reports, (c) clinical trial master files (or equivalent), (d) copies of completed and final non-clinical study reports used to support Regulatory Approvals, (e) copies of material
documents filed with a Regulatory Authority in connection with marketing authorizations, INDs and other regulatory filings and Regulatory Approvals in the applicable country that exist at the time of termination, (f) copies of correspondence
with Regulatory Authorities, and (g) copies of any then-existing documentation and technical information, in the form and format in which such materials are maintained by Pfizer in the ordinary course of its business, that are necessary for the
manufacture of the Licensed Product in the Reference Forms, which documentation and technical information shall include (1) copies of flow charts of the manufacturing procedures and work instructions related to manufacturing of the Licensed
Product in the Reference Forms, (2) a list of all equipment, including the source of the equipment, utilized in the production of the Licensed Product in the Reference Forms, (3) copies of all current specifications for the Licensed
Product in the Reference Forms, (4) copies of all standard operating procedures for the manufacturing procedures to be transferred, and (5) all environmental conditions necessary for the manufacture of the Licensed Product in the Reference
Forms and copies of any existing external environmental impact studies based on the materials or methods employed in the manufacturing method to be transferred, in each case that relates to a Licensed Product in the Reference Forms and that is in
the possession or control of Pfizer (including information controlled by Pfizer but in the possession of a Third Party). Pfizer shall bear its costs and expenses for the transfer described in this Section 9.5(e), subject to a limit of [* * *]
of meetings and an additional [* * *], and any additional support to be provided by Pfizer shall be provided on a person-hour basis at a 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 50 

 
rate and for a number of hours that will be agreed upon in advance between GMI and Pfizer, provided that GMI shall be responsible for any out-of-pocket expenses incurred by Pfizer in connection
with any such transfer to the extent Pfizer notifies GMI of such expenses prior to incurring them and GMI agrees to reimburse such expenses to Pfizer (and if GMI does not agree to reimburse such expenses to Pfizer, Pfizer shall not be obligated to
incur any such out-of-pocket expenses in connection with any such transfer). 
 (f) Pfizer agrees to assign and
hereby assigns to GMI all right, title and interest in and to any and all trademarks that are owned by Pfizer and that prior to termination have been and/or are being used at termination with respect to Licensed Product. 

9.6 Certain Payments after Termination. Notwithstanding anything to the contrary herein, in the event that (a) GMI requests
the license provided for in Section 9.5(b) or requests Pfizer to transfer or provide any of the data, information or documents provided for in Section 9.5(e) and (b) as of the date of termination of this Agreement by GMI or by Pfizer
under Section 9.2, Pfizer or its Affiliate has completed a Phase III Clinical Trial for a Licensed Product for an indication and GMI or its licensee files for and obtains Regulatory Approval for such Licensed Product for such indication based
on such Phase III Clinical Trial, or at the date of such termination Pfizer or its Affiliate has obtained Regulatory Approval for a Licensed Product for an indication, then GMI shall pay royalties to Pfizer on GMI Net Sales of such Licensed Product
for such indication at a royalty rate of [* * *] percent ([* * *]%) of GMI Net Sales at any time after the date of such termination for a period of ten (10) years from the First Commercial Sale of such Licensed Product for such indication;
provided that GMI only shall be obligated to make such payments to Pfizer until such time as the aggregate of payments due and payable under this Section 9.6 equal [* * *] dollars ($[* * *]). In the event that (1) the preceding
sentence is not applicable, (2) GMI requests the license provided for in Section 9.5(b) or requests Pfizer to transfer or provide any of the data, information or documents provided for in Section 9.5(e), and (3) as of the date of
termination of this Agreement by GMI or by Pfizer under Section 9.2, Pfizer or its Affiliate has completed an Additional Phase II Clinical Trial for a Licensed Product for an indication, the results of which Additional Phase II Clinical Trial
are supportive of and included in an application for Regulatory Approval for such indication, then GMI shall pay 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 51 

 
royalties to Pfizer on GMI Net Sales of such Licensed Product for such indication at a royalty rate of [* * *] percent ([* * *]%) of GMI Net Sales at any time after the date of such termination
for a period of ten (10) years from the First Commercial Sale of such Licensed Product for such indication; provided that GMI only shall be obligated to make such payments to Pfizer until such time as the aggregate of payments due and payable
under this Section 9.6 equal [* * *] Dollars ($[* * *]). GMI shall make such payments to Pfizer within forty-five (45) days of the end of each calendar quarter in which any payment under this Section 9.6 become due and payable and
each such payment shall be accompanied by a detailed written report showing the calculation of such payment. The provisions of Sections 4.2(f), 4.2(g), 4.3, 4.4, 4.5 and 4.6 shall apply, mutatis mutandis, to royalties payable by GMI under
this Section 9.6 and for purposes of this sentence all reference to one Party in such Sections shall be deemed to refer to the other Party and all references to a Pfizer Quarter shall be deemed to refer to a calendar quarter. 

9.7 Offset of Damages. In the event that Pfizer is awarded damages against GMI under this Agreement by a court of competent
jurisdiction as to which Pfizer’s right to collect such damages has not been stayed, in addition to any other remedy for collection of such damages, Pfizer may offset such damages against any amounts to be paid by Pfizer to GMI under this
Agreement. 
 9.8 Termination of Rights and Obligations. Upon termination of this Agreement all rights and obligations of
the Parties under this Agreement shall terminate except those that survive termination under Section 9.13. 
 9.9
Accrued Obligations. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including without
limitation the obligation to pay royalties for Licensed Product(s) sold prior to such expiration or termination. 
 9.10
Disposition of Inventory. Notwithstanding anything herein to the contrary, in the event of termination of this Agreement, at the option of Pfizer, Pfizer either (a) shall have for a period of [* * *] ([* * *]) months after termination,
the right to use or sell Licensed Products on hand on the date of such termination and to complete Licensed Products in the process of manufacture at the time of such termination and use or sell the same as if licensed under this

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 52 

 
Agreement, provided that Pfizer shall submit the applicable royalty report, along with the royalty payments required by this Agreement; or (b) at the request of GMI, shall transfer to GMI
all existing inventory, raw material, work-in-progress and finished goods, each with respect to any Compound and Licensed Product, at a cost to GMI equal to Pfizer’s fully-burdened manufacturing costs together with the reasonable cost of
transportation. 
 9.11 Pfizer Elections upon Breach by GMI. If an event occurs that gives rise to a right of termination
by Pfizer under Section 9.3 (as a result of an uncured material breach by GMI) and if Pfizer elects not to terminate this Agreement, Pfizer may elect that Sections 3.1(a) and (b), 3.2(b)(iii) shall be deleted, in whole or in part, from this
Agreement and Pfizer’s obligations to deliver reports pursuant to Section 3.2(b)(iv) shall be limited to [* * *]. If Pfizer makes any election as provided in this Section 9.11 to delete any Section, each of the Parties hereto will
enter into an appropriate and customary written amendment and no Party shall have any further obligations with respect to any such deleted Section. 
 9.12 Bankruptcy. All rights and licenses granted under Section 2.1 of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code,
licenses of rights to “intellectual property” as defined under Section 101(35A) of the U.S. Bankruptcy Code. The Parties agree that Pfizer, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of
its rights and elections under the U.S. Bankruptcy Code, and that upon commencement of a bankruptcy proceeding by or against GMI under the U.S. Bankruptcy Code, Pfizer shall be entitled to a complete duplicate of or complete access to any such
intellectual property and all embodiments of such intellectual property that is licensed to Pfizer under this Agreement. Such intellectual property and all embodiments thereof shall be promptly delivered to Pfizer (i) upon any such commencement
of a bankruptcy proceeding upon written request therefor by Pfizer, unless GMI elects to continue to perform all of its obligations under this Agreement or (ii) if not delivered under (i) above, upon the rejection of this Agreement by or
on behalf of GMI upon written request therefor by Pfizer. The term “embodiments” of intellectual property includes all tangible, intangible, electronic or other embodiments of rights and licenses hereunder, including all compounds and
products embodying intellectual property, Licensed Products, filings with Regulatory Authorities and related rights. The foregoing is without prejudice to any rights Pfizer may have arising under the U.S. Bankruptcy Code or other applicable law.

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 53 

 9.13 Survival. Following expiration or termination of this Agreement for any reason,
Articles 1, 6, 8, 9 and 11 and Sections 2.4, 3.1(c)(B) and 7.5 and Sections 4.3 and 4.4 with respect to royalties paid or to be paid under this Agreement shall survive the expiration or termination. 

Article 10 NON-COMPETITION 
 From the Effective Date until the end of the Term, GMI, its Affiliates and any Third Party on behalf of GMI or its Affiliates may not, directly or indirectly, commercialize in any country in the Territory
any pharmaceutical compound or product in any dosage form or formulation that is labeled for treatment or prevention or prophylaxis of a vaso-occlusive or painful crisis associated with Sickle Cell Disease (a “Competing Product”).
If GMI or any of its Affiliates controlling GMI (a “GMI Parent”) undergoes a Change of Control, then the provisions of the preceding sentence shall not apply with respect to a Competing Product; provided, however, that such
Competing Product is researched, developed and commercialized without use of any GMI Patent Rights or GMI Know-How. 
 Article
11 MISCELLANEOUS 
 11.1 Assignment. 

(a) Assignment. This Agreement and the rights and obligations under this Agreement may not be assigned by
operation of law or otherwise by either Party without the consent of the other Party, provided, however, that either Party may assign this Agreement, in whole or in part, without the consent of the other Party (i) to an Affiliate, or
(ii) to a successor, in each case by virtue of a sale of all or substantially all of its assets related to this Agreement, merger, consolidation or similar transaction or where a Party or its Affiliate is required, or makes a good faith
determination based on advice of counsel that it is required, to divest any of the Licensed Products in order to comply with Law or the order of any Governmental Authority as a result of merger of a Party with a Third Party or acquisition by a Party
of a Third Party or acquisition of a 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 54 

 
Party by a Third Party; provided, further, that the assigning Party shall deliver written notice of any such permitted assignment to the other Party, and the assignee shall assume all
obligations of its assignor under this Agreement and such assigning party shall remain jointly and severally liable with such assignee in respect of all obligations so assigned. Subject to the restriction on assignment of this Section 11.1,
this Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Parties. 

(b) Transfer of GMI Patent Rights. Except in connection with permitted assignments under Section 11.1(a) to a
Person that is not an Affiliate of GMI, GMI and any Affiliate of GMI may not sell, assign or otherwise transfer GMI Patent Rights to any person other than a wholly-owned direct or indirect subsidiary of GMI that (x) is and continues to be at
all times incorporated and domiciled (including with respect to principal headquarters) in any state of the United States of America and (y) prior to any such sale, assignment or transfer to such person described in clause (x), has acknowledged
and confirmed in writing to Pfizer, all in a manner reasonably acceptable to Pfizer, that, effective as of such sale, assignment or other transfer, such transferee shall be bound by this Agreement as if it were a party to it as and to the identical
extent applicable to the transferor with respect to GMI Patent Rights. 
 (c) Non-compliant Assignments.
Any purported assignment that is not in compliance with this Section 11.1 shall be null and void. 
 (d)
Performance by Affiliates. Pfizer shall have the right to permit an entity that is an Affiliate of Pfizer to exercise the rights and licenses granted to Pfizer under this Agreement without the granting of a sublicense while such entity is an
Affiliate of Pfizer, provided that the Affiliate agrees to be bound by the terms and conditions of this Agreement as if a signatory thereto. In exercising the rights and licenses granted under this Agreement, Pfizer shall have the right to have
Licensed Product in the Field researched, developed and/or made for Pfizer by a Third Party without granting a sublicense to such Third Party; provided, that such research, development and/or manufacture is performed for Pfizer, and Pfizer
shall ensure that any such Third Party shall perform such research, development or manufacturing activities in compliance with the provisions of this Agreement. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 55 

 11.2 Notices. Any consent, notice or report required or permitted to be given or made
under this Agreement by one of the Parties hereto to the other shall be in writing and shall be deemed given (i) five (5) Business Days after mailing when mailed by registered or certified mail, return receipt requested, postage paid, or
(ii) on the date received when delivered in person or by reputable international express delivery service, addressed to such other Party at its address indicated below, or to such other address as the addressee shall have last furnished in
writing to the addressor and shall be effective upon receipt by the addressee: 
 If to GMI: 

GlycoMimetics, Inc. 
 401 Professional Drive, Suite 250 
 Gaithersburg, Maryland 20879

 Attn: CEO 
 If to Pfizer: 
 Pfizer Inc. 

[XXXXX] 
 With a copy to: 
 Pfizer Inc. 

[XXXXX] 
 11.3 Jurisdiction. Except as to Patent Rights for which the patent laws of the country of the Patent Right shall be controlling, this Agreement shall be governed by and construed in accordance with
the laws of the State of New York, U.S.A, without regard to any choice of law 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 56 

 
principles that would dictate the application of the laws of another jurisdiction. All actions and proceedings under this Agreement shall be brought exclusively in a state or federal court of
competent subject matter jurisdiction in the County of New York in the State of New York. Each Party hereby waives (i) any objection which it may have at any time to the venue of the proceedings in any such court, (ii) any claim that such
proceedings have been brought in an inconvenient forum and (iii) the right to object, with respect to such proceedings, that such court does not have any jurisdiction over such Party. 

11.4 Dispute Resolution. Except as otherwise set forth in this Agreement, any disputes arising between the Parties relating to,
arising out of or in any way connected with this Agreement or any term or condition hereof, or the performance by either Party of its obligations hereunder, shall be resolved as follows: 

(a) Within [* * *] ([* * *]) days of notice of such dispute, the senior executive, or an equivalent successor thereto, to
be nominated by Pfizer who is responsible for the Licensed Product, or his or her designate, and the Chief Executive Officer of GMI or his or her designate shall first attempt to resolve such dispute through good faith negotiations for a period of
not less than [* * *] ([* * *]) days. 
 (b) If such dispute cannot be resolved after such
[* * *] ([* * *]) day period then either Pfizer or GMI may initiate a legal action with respect to such dispute. 
 (c) This Section 11.4 shall not prevent a Party from seeking and obtaining temporary or preliminary relief in a court of competent jurisdiction to protect the interests of such Party pending the
outcome of proceedings pursuant to this Section 11.4. 
 11.5 Entire Agreements; Amendments. 

(a) This Agreement, together with the Schedules and Exhibits hereto, contains the entire understanding of the Parties
with respect to the subject matter hereof and supersedes and terminates all prior and contemporaneous agreements and understandings between the Parties, whether oral or in writing, by and between Pfizer and GMI with respect to the subject matter
hereof and except as provided in Section 11.5(b), including but not limited to the Confidentiality Agreement between the Parties effective [* * *]. In the event of any conflict or inconsistency between any provision of any Schedules or Exhibit
hereto and any provision of 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 57 

 
this Agreement, the provisions of this Agreement shall prevail. All express or implied agreements and understandings, either oral or written, heretofore made are expressly merged in and made a
part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by the Parties hereto. Each of the Parties hereby acknowledges that this Agreement and the related documents are each the
result of mutual negotiation and, therefore, any ambiguity in their respective terms shall not be construed against the drafting Party. 
 (b) The Confidentially Agreement between the Parties effective [* * *] shall survive and remain in full force and effect only with respect to any breaches thereof prior to the Effective Date of this
Agreement. 
 11.6 Headings. The captions to the several Articles and Sections hereof and Schedules or Exhibits hereto
are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Articles and Sections hereof. 
 11.7 Third Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party, including any creditor of either party. Except for an
assignee in accordance with a permitted assignment of this Agreement, no Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation
(or otherwise) against either Party. 
 11.8 Independent Contractor. It is expressly agreed that GMI and Pfizer shall be
independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither GMI nor Pfizer shall have the authority to make any statements, representations or commitments of any
kind, or to take any action, which shall be binding on the other, without the prior written consent of the other Party to do so. 
 11.9 Waivers. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a
written instrument duly executed by or on behalf of the Party or parties waiving such term or condition. Neither the waiver by either Party hereto of any right hereunder nor the failure to perform or of a breach by the other Party shall not be
deemed or construed a waiver of 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 58 

 
any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. All rights, remedies, undertakings, obligations and agreements contained
in this Agreement shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement. 
 11.10 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
Counterparts may be exchanged by electronic portable document format if mutually agreed by the Parties. 
 11.11 Other
Actions. Each Party agrees to sign and execute such documents and to take such actions as reasonably requested by the other Party to carry out and perform the intent and purposes of the Party’s obligations under this Agreement. 

11.12 Severability. Each Party hereby agrees that it does not intend to violate any public policy, statutory or common laws,
rules, regulations, treaty or decision of any government agency or executive body thereof of any country or community or association of countries. Should one or more provisions of this Agreement be or become invalid or unenforceable, the Parties
hereto shall use their respective reasonable efforts to substitute, by mutual consent, valid provisions for such invalid provisions, if their economic effect, are sufficiently similar to the invalid provisions that it can be reasonably assumed that
the Parties would have entered into this Agreement based on such valid provisions. In case such alternative provisions cannot be agreed upon, the invalidity of one or several provisions of this Agreement shall not affect the validity of this
Agreement as a whole, unless the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid provisions. 

11.13 Construction. Except where the context otherwise requires, wherever used, the singular will include the plural, the plural
the singular, the use of any gender will be applicable to all genders, and the words “and/or” is used in the inclusive sense (one or more). The captions of this Agreement are for convenience of reference only and in no way define,
describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein means including, without limiting the

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 59 

 
generality of any description preceding such term. The term “owned” or “owns” means solely owned or owns, or jointly owned or owns. References to “Section” or
“Sections” or “Article” or “Articles” are references to the numbered Sections or Articles of this Agreement, unless expressly stated otherwise. 
 [Signature Page Follows] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 60 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and scaled by
their respective duly authorized representatives as of the date first set forth above. 
  

									
	GLYCOMIMETICS, INC.	 		 	PFIZER INC.
					
	By:	 	/s/ Rachel K. King	 		 	By:	 	/s/ Adam Woodrow
					
	Name:	 	Rachel K. King	 		 	Name:	 	Adam Woodrow
					
	Title:	 	CEO	 		 	Title:	 	Vice President Commercial Development

 EXHIBIT A 
 GMI PATENT RIGHTS 
  

							
	 Nation /

Region
	 	 Application No. /

Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation /

Region
	 	 Application No. /

Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation /

Region
	 	 Application No. /

Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 Schedule 1.10 
 Backup Compounds 
 SEE NEXT PAGE 

[* * *] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 Schedule 1.35 
 Knowledge of GMI 
 PART A 
 Rachel K. King, President and Chief Executive Officer 
 John L. Magnani, Ph.D., Vice President and
Chief Scientific Officer 
 Helen M. Thackray, M.D., FAAP, Vice President, Clinical Development 

Brian Hahn, Director, Finance and Administration 
 PART B 
 [* * *] 
 [* * *] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 Schedule 1.69 
 [* * *] 
 [See Attached] 

[* * *] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 Schedule 2.1 
 Permitted Studies 
  

									
	 Indication
	 	 Institution
	 	 Investigator(s)
	 	 Summary
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 Schedule 2.3 
 Transition Plan 
 [* * *] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 Schedule 3.1(c) 
 Ongoing Clinical Trial Budget 
  

													
	 	  	Budget	 	 	To
Date	 	 	Remaining	 
	 	  	Jun-11	 
				
	 [* * *]
	  	 	[* * *	] 	 	 	[* * *	] 	 	 	[* * *	] 
				
	 [* * *]
	  	 	[* * *	] 	 	 	[* * *	] 	 	 	[* * *	] 
				
	 [* * *]
	  	 	[* * *	] 	 	 	[* * *	] 	 	 	[* * *	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 
		  	 	[* * *	] 	 	 	[* * *	] 	 	 	[* * *	] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 Schedule 6.4 
 Public Announcement 
  
 

 
 PRESS RELEASE 
 DRAFT – NOT INTENDED FOR DISTRIBUTION 
 GlycoMimetics and Pfizer
Enter into Licensing Agreement for Drug Candidate 
 Currently in Development to Treat Patients Experiencing Vaso-occlusive
Crisis 
 Associated with Sickle Cell Disease 
 Gaithersburg, MD – October 11, 2011 – GlycoMimetics, Inc. announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) for
the GlycoMimetics investigational compound GMI-1070. GMI-1070 is a pan-selectin antagonist currently in Phase 2 development for the treatment of vaso-occlusive crisis associated with sickle cell disease. GMI-1070 has received Orphan
Drug and Fast Track status from the U.S. Food and Drug Administration (FDA). 
 Vaso-occlusive crisis, which can last five to six days on
average, results in over 75,000 hospitalizations each year in the U.S. These crises cause pain and tissue damage leading to multiple organ damage, a requirement for life-long narcotic pain medications, and eventually to significantly shorter life
spans. While the genetic and molecular cause of sickle cell disease has been known for more than 50 years, therapy for painful crises has not significantly advanced. GMI-1070 is thought to inhibit selectin interactions, a key early step in the
inflammatory process leading to vaso-occlusive crisis. In preclinical studies, GMI-1070 restored blood flow to affected vessels of sickle cell animals experiencing vaso-occlusive crisis. 
 “We are very pleased to partner with Pfizer for the advancement of GlycoMimetics’ lead drug candidate, GMI-1070, which is initially being evaluated in patients with sickle cell disease
experiencing vaso-occlusive crisis. This is a major unmet medical need,” said Rachel King, CEO of GlycoMimetics. “We value the resources and experience that Pfizer brings to the program, and recognize that the agreement is an
important validation of GlycoMimetics’ unique chemistry expertise in discovery of proprietary drug candidates.” 
 Under the terms of
the agreement, Pfizer will receive an exclusive worldwide license to GMI-1070 for vaso-occlusive crisis associated with sickle cell disease and for other diseases for which the drug candidate may be developed. GlycoMimetics will remain responsible
for completion of the ongoing Phase 2 trial under Pfizer’s oversight, and Pfizer will then assume all further development and commercialization responsibilities. The potential value of the agreement for GlycoMimetics is approximately $340
million, including an upfront payment as well as development, regulatory and commercial milestones. GlycoMimetics is also eligible for royalties on any sales. 
 “Pfizer is committed to helping improve the lives of patients with rare diseases, and we see potential for GlycoMimetics’ GMI-1070 to be a significant advance in the treatment of vaso-occlusive
crisis of sickle 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 
cell disease,” said Yvonne Greenstreet, senior vice president and head of the Medicines Development Group within Pfizer’s Specialty Care business unit. “This experimental compound
and partnership are emblematic of our strategy in rare disease, targeting areas of high unmet need to deliver improved patient outcomes.” 

“This partnership is an important milestone for GlycoMimetics as the company advances its clinical development program,” added Jim Barrett,
Ph.D., Chairman of the Board of GlycoMimetics and General Partner, New Enterprise Associates. “It’s a testament to the progress made to date with GMI-1070, and will enhance continued development of this potential treatment for patients
suffering from vasoocclusive crisis.” 
 About GMI-1070 
 GMI-1070 is a rationally designed glycomimetic inhibitor of E-, P- and L-selectins that interferes in a key early step in the inflammatory process leading to leukocyte adhesion and recruitment to inflamed
tissue. GMI-1070 has shown activity in several models of diseases in which leukocyte adhesion and activation play a key role. 
 GMI-1070 is
initially being developed for the treatment of vaso-occlusive crisis associated with sickle cell disease. By inhibiting selectin interactions, GMI-1070 may be able to decrease the enhanced cell adhesion that results in vaso-occlusive crisis. In
preclinical studies, GMI-1070 restored blood flow to affected vessels of sickle cell animals experiencing vaso-occlusive crisis. Two Phase 1 trials of GMI-1070 were successfully completed in the first quarter of 2009, with no serious adverse events
reported. The program is currently in Phase 2 clinical testing. GMI-1070 is also being evaluated in preclinical studies for the treatment of other diseases, including hematologic malignancies, where selectin-mediated cell adhesion and migration is
known to play a key role in the disease process. 
 Issued U.S. patents cover GMI-1070 with additional intellectual property issued and pending
outside the U.S. 
 About Sickle Cell Disease and Vaso-Occlusive Crisis 
 Vaso-occlusive crisis is the main clinical feature of sickle cell disease, causing severe pain, often resulting in significant patient complications, and sometimes death. Currently, there are no
mechanism-based therapies for treatment of vaso-occlusive crisis. Treatment consists primarily of supportive therapy in the form of hydration and pain control, typically requiring hospitalization for five to six days. 

About GlycoMimetics, Inc. 
 GlycoMimetics
is a privately held biotechnology company that capitalizes on advances in the field of glycobiology. The company uses rational design of small molecule drugs that mimic the functions of bioactive carbohydrates to develop new drug candidates. The
company’s initial focus is on therapeutics to treat orphan conditions in which inflammation and cell adhesion may play a key role. For additional information, please visit the company’s website: www.glycomimetics.com. 

# # # 
 MEDIA CONTACTS

 GlycoMimetics: 
 Brian
Hahn 
 Phone: 240-243-1207 
 Email
Address: bhahn@glycomimetics.com 

 Schedule 7.1 
 Disclosure Schedules 
 [* * *] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 AMENDMENT NO. 1 TO LICENSE AGREEMENT 

This AMENDMENT NO. 1 TO LICENSE AGREEMENT (the “First Amendment”) is made and entered into as of November 17, 2011 by and
between GLYCOMIMETICS, INC., a Delaware corporation having a place of business at 401 Professional Drive, Suite 250, Gaithersburg, Maryland 20879 (“GMI”), and PFIZER INC., a Delaware corporation having a place of business at 235 East 42nd
Street, New York, New York 10017 (“Pfizer”). GMI and Pfizer are individually referred to as a “Party” or collectively as the “Parties”. 
 WHEREAS, GMI and Pfizer are parties to a License Agreement dated as of October 7, 2011, (the “License Agreement”); 
 WHEREAS, the Parties desire to amend the License Agreement by including therein certain patents and patent applications owned by GMI that were erroneously omitted from Exhibit A of the License Agreement;
and 
 NOW, THEREFORE, in consideration of the mutual promises and agreement set forth herein, the Parties hereby agree as
follows: 
 1. GMI and Pfizer agree that Exhibit A of the License Agreement is replaced by the Exhibit A attached
hereto and the License Agreement is to be construed as if the replacement Exhibit A was attached thereto as of the Effective Date of such License Agreement. The representations and warranties of GMI under Article 7 of such License Agreement with
respect to GMI Patent Rights of Exhibit A shall be deemed to have been and are made as of the Effective Date of such License Agreement, with respect to all of the patents and patent applications of such replacement Exhibit A. 

2. This First Amendment amends the terms of the License Agreement as expressly provided above, and the License Agreement
as so amended remains in full force and effect. Capitalized terms used but not defined herein shall have the meanings set forth in the License Agreement. The validity, performance, construction, and effect of this First Amendment shall be governed
by and construed under the substantive laws of the State of New York, without regard to any choice of law principles that would dictate the application of the laws of another jurisdiction. This First Amendment may be executed in counterparts, all of
which taken together shall be regarded as one and the same instrument. 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 IN WITNESS WHEREOF, the Parties have executed this First Amendment in duplicate originals by
their proper officers as of the date specified above. 
  

									
	GLYCOMIMETICS, INC.	 		 	PFIZER INC.
					
	By: 	 	/s/ Rachel K. King	 		 	By: 	 	/s/ Robert Bagdorf
	Name: Rachel K. King	 		 	Name: Robert Bagdorf, MD, MBA
	Title: CEO	 		 	Title: VP, Worldwide Business Development
	Date: Nov. 18, 2011	 		 	Date: 11/17/2011

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 Exhibit A 
 GMI PATENT RIGHTS 
  

							
	 Nation/Region
	 	 Application No. / Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation/Region
	 	 Application No. / Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation/Region
	 	 Application No. / Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation/Region
	 	 Application No. / Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation/Region
	 	 Application No. / Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation/Region
	 	 Application No. / Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 AMENDMENT NO. 2 TO LICENSE AGREEMENT 

This AMENDMENT NO. 2 TO LICENSE AGREEMENT (the “Second Amendment) is made and entered into as of December 1, 2012 by and between GLYCOMIMETICS,
INC., a Delaware corporation having a place of business at 401 Professional Drive, Suite 250, Gaithersburg, Maryland 20879 (“GMI”), and PFIZER INC., a Delaware corporation having a place of business at 235 East 42nd Street, New York, New
York 10017 (“Pfizer”). GMI and Pfizer are individually referred to as a “Party” or collectively as the “Parties”. 
 WHEREAS, GMI and PFIZER are parties to a License Agreement dated as of October 7, 2011, (the “License Agreement”) as amended, November 17, 2011 (“Amendment No. 1”);

 WHEREAS, the Parties desire to amend the License Agreement by including therein certain patents and patent
applications owned by GMI that were erroneously omitted from Exhibit A of the License Agreement; and 
 WHEREAS,
the Parties desire to amend the License Agreement by deleting the Topline Study Report template (Schedule 1.69 in the License Agreement) and replacing it in its entirety with the revised Top Line Report template attached hereto and made a part
hereof; and 
 NOW, THEREFORE, in consideration of the mutual promises and agreement set forth herein, the Parties
hereby agree as follows: 
  

	 	1.	GMI and Pfizer agree that Exhibit A of the License Agreement is replaced by the Exhibit A attached hereto and the License Agreement is to be construed as if the
replacement Exhibit A was attached thereto as of the Effective Date of such License Agreement. The representations and warranties of GMI under Article 7 of such License Agreement with respect to GMI Patent Rights of Exhibit A shall be deemed to have
been made as of the Effective Date of such License Agreement, with respect to all of the patents and patent applications of such replacement Exhibit A. 

  

	 	2.	GMI and Pfizer agree to delete in its entirety the Topline Study Report template as set forth in Schedule 1.69 (Format for Topline Study Report) of the License
Agreement and replacing it with the Top Line Report template attached hereto and made a part hereof. 

  

	 	3.	 This Second Amendment amends the terms of the License Agreement, as amended, as expressly provided above, and the License Agreement as so amended
remains in full force and effect. Capitalized terms used but not defined herein 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 1. 

	 	
shall have the meanings set forth in the License Agreement. The validity, performance, construction, and effect of this Second Amendment shall be governed by and construed under the substantive
laws of the State of New York, without regard to any choice of law principles that would dictate the application of the laws of another jurisdiction. This Second Amendment may be executed in counterparts, all of which taken together shall be
regarded as one and the same instrument. 

 IN WITNESS WHEREOF, the Parties have executed this Second
Amendment in duplicate originals by their proper officers as of the date specified above. 
  

									
	GLYCOMIMETICS, INC.	 		 	PFIZER, INC.
					
	By: 	 	/s/ Rachel K. King	 		 	By: 	 	/s/ Y. Greenstreet
	Name: Rachel K. King	 		 	Name: Y. Greenstreet
	Title: CEO	 		 	Title: SVV Development
	Date: Dec. 14, 2012	 		 	Date: 12/06/12

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
 2. 

  
 

 
 Protocol GMI-1070-201 
 TOP LINE REPORT 
 [Schedule 1.69 TEMPLATE] 

[* * *] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

 Exhibit A 
 GMI PATENT RIGHTS 
  

							
	 Nation/Region
	 	 Application No./Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation/Region
	 	 Application No./Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation/Region
	 	 Application No./Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  

							
	 Nation/Region
	 	 Application No./Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation/Region
	 	 Application No./Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation/Region
	 	 Application No./Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

 [* * *] 
  

							
	 Nation/Region
	 	 Application No./Patent No.
	 	 Filing Date
	 	 Status

	 [* * *]
	 	[* * *]	 	[* * *]	 	[* * *]

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS 

THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [* * *]. A COMPLETE 

VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.EX-10.2

 Exhibit 10.2 
 SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 THIS AMENDED AND
RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of the 20th day of October, 2009 by and among GlycoMimetics, Inc., a Delaware corporation (the “Company”), and the investors listed on Exhibit
1.01, as updated from time to time, hereto (the “Investors”) and each Person who shall, after the date hereof, acquire shares of Series A-1 Preferred Stock of the Company pursuant to (A) the Purchase Agreement (as defined below)
or (B) a transfer of shares of Restricted Stock (as defined below) wherein rights under this Agreement are validly assigned, and joins in and becomes a party to this Agreement by executing and delivering to the Company a counterpart signature
page in the form attached hereto and who shall be listed on an updated Exhibit 1.01, each of which is also herein referred to as an “Investor” and collectively as the “Investors.” 

RECITALS 

WHEREAS, the Company and certain of the Investors are parties to the Series A-1 Convertible Preferred Stock Purchase Agreement of even
date herewith (the “Purchase Agreement;” such Investors, the “Series A-1 Investors”); 
 WHEREAS, the
Company and certain of the Investors are parties to that certain Amended and Restated Investor Rights Agreement dated as of June 19, 2006 (the “Prior Investor Rights Agreement”); 

WHEREAS, in order to induce the Series A-1 Investors to enter into the Purchase Agreement, and purchase shares of Series A-1 Convertible
Preferred Stock, par value $0.001 per share (the “Series A-1 Preferred Stock,” and together with any other shares of the Company’s Preferred Stock issued after the date hereof, the “Preferred Shares”), immediately prior to
execution of the Purchase Agreement and this Agreement, all outstanding shares of the Company’s previously existing Series A Preferred Stock and Series B Preferred Stock converted into Common Stock (such Common Stock received upon conversion of
such previously existing Series A Preferred Stock and Series B Preferred Stock, as detailed on Exhibit 1.01 attached hereto, the “Converted Shares”); and 
 WHEREAS, in order to induce the Series A-1 Investors to enter into the Purchase Agreement, and purchase shares of Series A-1 Convertible Preferred Stock thereunder, the parties hereto desire to amend and
restate the Prior Investor Rights Agreement to read in its entirety as set forth in this Agreement. 
 NOW, THEREFORE, in
consideration of the foregoing and of the mutual covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which hereby are acknowledged, the parties hereby agree as follows:

 1. Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings:

 “Affiliate” shall mean, with respect to a Person, any other Person controlling, controlled by, or under
common control or otherwise under common investment management with such Person; provided, however that, with respect to Anthem Capital II, L.P. (“Anthem”), the term “Affiliate” shall include the United States Small
Business Administration and any third party approved by the Board of 

 
Directors, with respect to Novartis Bioventures Ltd., the term “Affiliate” shall mean: (x) any direct or indirect subsidiary of Novartis AG, (y) any foundation sponsored by
Novartis AG or its direct or indirect subsidiaries, and (z) any co-investment funds of Novartis, provided that such co-investment funds, which are (or will be) organized as limited partnerships, meet the following criteria: (i) the
general partner of such limited partnership is a wholly owned direct or indirect subsidiary of Novartis AG; (ii) the general partner of such limited partnership manages any such co-investment fund; and (iii) the limited partners of the
limited partnership are directors and/or employees of Novartis AG or its direct or indirect subsidiaries. 
 “Board of
Directors” shall mean the board of directors of the Company as constituted from time to time. 

“Code” shall mean the Internal Revenue Code of 1986, as amended from time to time. 

“Commission” shall mean the Securities and Exchange Commission, or any other federal agency at the time administering
the Securities Act. 
 “Common Stock” shall mean the Common Stock, $0.001 par value, of the Company, as
constituted as of the date of this Agreement. 
 “Computer Programs” shall mean (i) any and all computer
programs (consisting of sets of statements or instructions to be used directly or indirectly in a computer in order to bring about a certain result), and (ii) all associated data and compilations of data, regardless of their form or embodiment.
“Computer Programs” shall include, without limitation, all source code, object code and natural language code therefor, all versions thereof, all screen displays and designs thereof, all component modules, all descriptions, flow-charts and
other work product used to design, plan, organize and develop any of the foregoing, and all documentation, including without limitation user manuals and training materials, relating to any of the foregoing. 

“Conversion Shares” shall mean shares of Common Stock issued or issuable upon conversion of the Preferred Shares.

 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations of
the Commission thereunder, all as the same shall be in effect at the time. 
 “Intellectual Property Rights”
shall mean all of the following: (i) patents, patent applications, patent disclosures and all related continuation, continuation-in-part, divisional, reissue, re-examination, utility, model, certificate of invention and design patents, patent
applications, registrations and applications for registrations, (ii) trademarks, service marks, trade dress, logos, tradenames, service names and corporate names and registrations and applications for registration thereof, (iii) copyrights
and registrations and applications for registration thereof, (iv) mask works and registrations and applications for registration thereof, (v) trade secrets and confidential business information, whether patentable or nonpatentable and
whether or not reduced to practice, know-how, manufacturing and product processes and techniques, research and development information, copyrightable works, financial, marketing and business data, pricing and cost information, business and marketing
plans and customer and supplier lists and information, (vi) Computer Programs, (vii) other proprietary rights relating to any of the foregoing (including without limitation associated goodwill and remedies against infringements thereof and
rights of protection of an interest therein under the laws of all jurisdictions) and (viii) copies and tangible embodiments thereof. 

 “Key Employee” or “Key Employees” shall mean and include the
President, chief executive officer, chief financial officer, chief operating officer, chief technology officer, vice presidents of operations, research, development, sales or marketing, or any other individual who performs a significant role in the
operations of the Company or a Subsidiary as may be reasonably designated by the Board of Directors of the Company. 

“Major Investor” shall mean any Investor who holds at least 1,000,000 Preferred Shares (as adjusted for stock splits,
stock dividends, combinations, subdivisions, recapitalizations and similar events); for purposes of this definition, shares held by Affiliates of an Investor shall be aggregated for purposes of determining whether any Investor is a “Major
Investor” under this Agreement. 
 “Material Adverse Change” shall mean a material adverse change in the
business, operations, affairs, or financial condition of the Company. 
 “NEA” shall mean New Enterprise
Associates 13, L.P. 
 “Person or Persons” shall mean an individual, corporation, partnership, joint venture,
trust, or unincorporated organization, or a government or any agency or political subdivision thereof. 
 “Qualified
Public Offering” shall mean a fully underwritten, firm commitment public offering pursuant to an effective registration under the Securities Act covering the offer and sale by the Company of its Common Stock in which the aggregate net
proceeds to the Company equal or exceed $36,000,000, in which the price per share of such Common Stock equals or exceeds $3.80 per share (such price subject to adjustment in the event of any stock splits, stock dividends, combinations, subdivisions,
reorganizations and similar events). 
 “Registration Expenses” shall mean the expenses so described in
Section 8. 
 “Reserved Employee Shares” shall mean shares of Common Stock and options, warrants
and other rights to acquire Common Stock, and Common Stock issued pursuant to such options, warrants and other rights (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) issued or reserved for issuance under
the Company’s 2003 Stock Incentive Plan, as amended and as adopted and approved by the Board of Directors, not to exceed in the aggregate 4,829,003 shares of Common Stock (as appropriately adjusted in accordance with the Company’s Amended
and Restated Certificate of Incorporation and to reflect stock splits, stock dividends, combinations of shares and the like with respect to the Common Stock). 
 “Restated Certificate” shall mean the Company’s Amended and Restated Certificate of Incorporation. 
 “Restricted Stock” shall mean (i) the Conversion Shares and any other shares of Common Stock acquired by any of the Investors after the date hereof and (ii) the Converted
Shares, but excluding in either case any such shares which have been (a) registered under the Securities Act pursuant to an effective registration statement filed thereunder and disposed of in accordance with the registration statement covering
them or (b) publicly sold pursuant to Rule 144 under the Securities Act. 

 “Securities Act” shall mean the Securities Act of 1933, as amended, and the
rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 “Selling
Expenses” shall mean the expenses so described in Section 8. 
 “Series A-1 Directors”
shall mean the Company’s directors designated by NEA pursuant to Section 5(ii)(b) of the Stockholders Agreement. 
 “Stockholders Agreement” shall mean the Second Amended and Restated Stockholders Agreement, of even date herewith, by and among the Company and the “Stockholders” (as defined
therein). 
 “Subsidiary” or “Subsidiaries” shall mean any corporation, partnership, trust or other
entity of which the Corporation and/or any of its other subsidiaries directly or indirectly owns at the time a majority of the outstanding shares of equity securities of such corporation, partnership, trust or other entity. 

2. Restrictive Legend. Each certificate representing Preferred Shares, Conversion Shares or Restricted Stock shall, except as
otherwise provided in this Section 2 or in Section 3, be stamped or otherwise imprinted with a legend substantially in the following form (in addition to any legends required under applicable state securities laws or
regulations): 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933
OR APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE SOLD, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT FOR SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933 AND APPLICABLE STATE SECURITIES LAWS, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE REASONABLY SATISFACTORY TO THE COMPANY WITH RESPECT TO THE AVAILABILITY
OF AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE SECURITIES ACT OF 1933 AND APPLICABLE STATE SECURITIES LAWS. THE VOTING RIGHTS WITH RESPECT TO, AND SALE OR OTHER DISPOSITION OF, THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE RESTRICTED
BY AND SUBJECT TO THE PROVISIONS OF A SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT DATED AS OF OCTOBER 20, 2009 AS AMENDED FROM TIME TO TIME. A COPY OF WHICH IS AVAILABLE FOR INSPECTION AT THE OFFICES OF THE COMPANY.”

 A certificate shall not bear such legend immediately prior to, and following, any disposition of securities pursuant to Sections 4,
5, or 6 or in any case where such legend is determined not to be required under Section 3 hereof. 

3. Notice of Proposed Transfer. Prior to any proposed transfer of any Preferred Shares, Conversion Shares or Restricted Stock
(other than under the circumstances described in Sections 4, 5 

 
or 6 hereof), the holder thereof shall give written notice to the Company of its intention to effect such transfer. Each such notice shall describe the manner of the proposed transfer and,
if requested by the Company, shall be accompanied by an opinion of counsel reasonably satisfactory to the Company (it being agreed that Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP shall be satisfactory counsel) or other
evidence reasonably satisfactory to the Company to the effect that the proposed transfer may be effected without registration under the Securities Act and any applicable state securities laws (it being understood that no such evidence shall be
required with respect to any transfer made to one or more partners, members or Affiliates of the transferor), whereupon (subject to the other provisions of this Section 3) the holder of such stock shall be entitled to transfer such stock
in accordance with the terms of its notice. Each certificate for Preferred Shares, Conversion Shares or Restricted Stock transferred as above provided shall bear the legend set forth in Section 2, except that such certificate shall not
bear such legend if (i) such transfer is in accordance with the provisions of Rule 144 (or any other rule permitting public sale without registration under the Securities Act) or (ii) the opinion of counsel referred to above is to the
further effect that the transferee and any subsequent transferee (other than an affiliate of the Company) would be entitled to transfer such securities in a public sale without registration under the Securities Act. Any transferee of stock for which
a legend is required to be borne pursuant to the preceding sentence shall, as a condition to such transfer, execute and deliver to the Company a representation letter in form and substance reasonably satisfactory to the Company’s counsel to the
effect that the transferee is acquiring such stock for its own account, for investment purposes and not with a view to the distribution thereof. 
 4. Required Registration. 
 (a) Subject to Section 4(b) below,
at any time after the earlier of the third anniversary of the date of this Agreement or six months after the closing of an initial public offering, the holders of Restricted Stock constituting at least 40% in interest of the Conversion Shares then
outstanding may request the Company to register under the Securities Act all or any portion of the Restricted Stock (but not less than an amount of Restricted Stock that would result in an anticipated aggregate offering price, net of selling
expenses, of ten million dollars ($10,000,000)) for sale in the manner specified in such notice. Notwithstanding anything to the contrary contained herein, no request may be made under this Section 4 within 180 days after the effective
date of any registration statement on Form S-1 filed by the Company. All registration pursuant to this Section 4(a) are referred to herein as “Demand Registrations.” 

(b) Following receipt of any notice under this Section 4, the Company shall immediately notify all holders of Restricted
Stock and Preferred Shares from whom notice has not been received and such holders shall then be entitled within 30 days thereafter to request the Company to include in the requested registration all or any portion of their shares of Restricted
Stock. The Company shall use its reasonable best efforts to register under the Securities Act, for public sale in accordance with the method of disposition described in paragraph (a) above, the number of shares of Restricted Stock
specified in such notice (and in all notices received by the Company from other holders within 30 days after the giving of such notice by the Company). The Company shall not be obligated to effect, or to take any action to effect, any registration
of Restricted Stock pursuant to this Section 4 after the Company has effected registrations on two occasions pursuant to Section 4(a) and such registrations have been declared or ordered effective; provided,
however, that a registration shall be deemed to be effected only when a registration statement covering at least 85% of the shares of Conversion Shares specified in notices received as aforesaid for sale in accordance with the method of
disposition specified by the requesting holders shall have become effective or if such registration 

 
statement has been withdrawn prior to the consummation of the offering at the request of the holders of a majority of the Conversion Shares to be registered pursuant thereto (other than as a
result of a Material Adverse Change). 
 (c) The Company shall be entitled to include in any registration statement referred to
in this Section 4 shares of Common Stock to be sold by the Company for its own account, except as and to the extent that, in the opinion of the managing underwriter, such inclusion would adversely affect the marketing of the Restricted
Stock to be sold. Except for registration statements on Form S-4 or registrations relating solely to employee benefit plans on Forms S-1 or S-8 or any successors thereto, the Company will not file with the Commission any other registration statement
with respect to its Common Stock, whether for its own account or that of other stockholders, from the date of receipt of a notice from requesting holders requesting sale pursuant to an underwritten offering pursuant to this Section 4
until the completion of the period of distribution of the registration contemplated thereby. 
 (d) If in the opinion of the
managing underwriter the inclusion of all of the Restricted Stock requested to be registered under this Section would adversely affect the marketing of such shares, shares to be sold by the holders of Restricted Stock, if any, shall be excluded only
after any shares to be sold by the Company have been excluded. 
 (e) Unless the holders requesting a Demand Registration have
been able to include all of the Restricted Stock requested by such holders in such Demand Registration, the Company shall not include in such Demand Registration any securities which are not Restricted Stock. If a Demand Registration is an
underwritten offering and the managing underwriters advise the Company in writing that in their opinion the number of shares of Restricted Stock and, if permitted hereunder, other securities requested to be included in such registration exceeds the
number which can be sold in an orderly manner in such offering within a price range reasonably acceptable to the holders of Conversion Shares making such Demand Registration, the Company shall include in such registration: (i) first, Conversion
Shares pro rata among the holders of such Conversion Shares on the basis of the number of Conversion Shares owned by such holders, (ii) the Restricted Stock other than Conversion Shares, pro rata among the holders of such Restricted
Stock other than Conversion Shares on the basis of the number of shares (other than Conversion Shares) owned by such holders, and (iii) third, securities for the Company’s account and (iv) fourth, other securities which are not
Restricted Stock requested to be included in such registration pursuant to contractual obligation rights, pro rata among the holders thereof on the basis of the number of their securities requested to be included therein. 

5. Incidental Registration. If (but without obligation to do so) the Company at any time (other than pursuant to
Section 4 or Section 6) proposes to register any of its securities under the Securities Act for sale to the public solely for cash, whether for its own account or for the account of other security holders or both (except with
respect to registration statements relating solely to employee benefit plans on Forms S-1 or S-8, registration statements on Form S-4, or registration statements on another form not available for registering the Restricted Stock for sale to the
public), each such time it will give written notice to all holders of outstanding Restricted Stock of its intention so to do. Upon the written request of any such holder, received by the Company within 30 days after the giving of any such notice by
the Company, to register any of its Restricted Stock, the Company will use its reasonable best efforts to cause the Restricted Stock as to which registration shall have been so requested to be included in the securities to be covered by the
registration statement proposed to be filed by the Company. In the event that any registration pursuant to this Section 5 shall be, in 

 
whole or in part, an underwritten public offering, the number of shares of Restricted Stock to be included in such an underwriting may be reduced in accordance with Section 4(e) above
if and to the extent that the managing underwriter shall be of the opinion that such inclusion would adversely affect the marketing of the securities to be sold by the Company therein, provided, however, that such number of shares of
Restricted Stock shall not be reduced if any shares are to be included in such underwriting for the account of any person other than the Company or requesting holders of Restricted Stock, and provided, further, however, that in
no event may less than 20% of the total number of shares of Common Stock to be included in such underwriting be made available for shares of Restricted Stock (except that in the case of the initial public offering only if the managing underwriter
shall in good faith advise the holders proposing to distribute their securities through such underwriting that such level of participation would, in its opinion, materially adversely affect the offering price or its ability to complete the offering,
in which case the number of shares of Restricted Stock included shall be further reduced to such number which, in the opinion of the managing underwriter, can be included in the registration and underwriting without such an effect). 

6. Registration on Form S-3. If at any time (i) a holder or holders of Restricted Stock then outstanding requests in writing
that the Company file a registration statement on Form S-3 or any successor thereto for a public offering of all or any portion of the shares of Restricted Stock held by such requesting holder or holders, and (ii) the Company is a registrant
entitled to use Form S-3 or any successor thereto to register such shares, then the Company shall use its reasonable best efforts to register under the Securities Act on Form S-3 or any successor thereto, for public sale in accordance with the
method of disposition specified in such notice, the number of shares of Restricted Stock specified in such notice; provided, however, the Company shall not be required to effect any such registration, qualification or compliance pursuant to
this Section 6 if (x) Form S-3 is not available for such offering by the holders of Restricted Stock; (y) the holders of Restricted Stock, together with the holders of any other securities of the Company entitled to inclusion
in such registration, propose to sell Restricted Stock and other securities of less than $1,000,000; (z) the Company shall furnish to the holders of Restricted Stock a certificate signed by the President of the Company stating that, in the good
faith judgment of the Board of Directors of the Company, it would be materially detrimental to the Company and its stockholders for such Form S-3 registration to be effected at such time, in which event the Company shall have the right to defer the
filing of the Form S-3 registration statement for a period not more than 60 days after the receipt of the request of the holder or holders of Restricted Stock under this Section 6; provided, however, that the Company shall
not defer more than two filings of the Form S-3 in any 12 month period; (xx) the Company has, within the 12 month period preceding the date of such request, already effected two registrations on Form S-3 for the holders of Restricted Stock
pursuant to this Section 6, or (yy) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or
compliance. Whenever the Company is required by this Section 6 to use its reasonable best efforts to effect the registration of Restricted Stock, each of the procedures and requirements of Section 4 (including but not limited
to the requirement that the Company notify all holders of Restricted Stock from whom notice has not been received and provide them with the opportunity to participate in the offering) shall apply to such registration. 

7. Registration Procedures. If and whenever the Company is required by the provisions of Sections 4, 5 or 6
to use its reasonable best efforts to effect the registration of any shares of Restricted Stock under the Securities Act, the Company will, as expeditiously as possible: 
 (a) prepare and file with the Commission a registration statement (which, in the case of an initial public offering pursuant to Section 4, shall be on Form S-1 or other form of general
applicability satisfactory to the managing underwriter selected as therein provided) with respect to such securities and use its reasonable best efforts to cause such registration statement to become and remain effective for the period of the
distribution contemplated thereby (determined as hereinafter provided); 

 (b) prepare and file with the Commission such amendments and supplements to such
registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for the period specified in paragraph (a) above and comply with the provisions of the Securities Act
with respect to the disposition of all securities covered by such registration statement in accordance with the sellers’ intended method of disposition set forth in such registration statement for such period; 

(c) furnish to each seller of Restricted Stock and to each underwriter such number of copies of the registration statement and the
prospectus included therein (including each preliminary prospectus) as such persons reasonably may request in order to facilitate the public sale or other disposition of the Restricted Stock covered by such registration statement; 

(d) use its best efforts to register or qualify the Restricted Stock covered by such registration statement under the securities or
“blue sky” laws of such jurisdictions as the sellers of Restricted Stock or, in the case of an underwritten public offering, the managing underwriter shall reasonably request, provided, however, that the Company shall not for
any such purpose be required to qualify to transact business as a foreign corporation in any jurisdiction where it is not so qualified or to consent to general service of process in any such jurisdiction; 

(e) use its reasonable best efforts to list the Restricted Stock covered by such registration statement with any securities exchange or
national quotation system on which the Common Stock of the Company is then listed; 
 (f) provide a transfer agent and
registrar, as well as a CUSIP number, for all such Restricted Stock, not later than the effective date of such registration statement; 
 (g) notify each seller of Restricted Stock and each underwriter under such registration statement, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of
the happening of any event of which the Company has knowledge as a result of which the prospectus contained in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required
to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 

(h) if the offering is underwritten and at the request of any seller of Restricted Stock, use its best efforts to furnish on the date
that Restricted Stock is delivered to the underwriters for sale pursuant to such registration: (i) an opinion, dated such date, of counsel representing the Company for the purposes of such registration, in form and substance as is customarily
given to underwriters in an underwritten public offering, addressed to the underwriters and to such seller, and (ii) a letter dated such date, from the independent public accountants of the Company, addressed to the underwriters and to such
seller, in a form and substance as is customarily given by independent public accountants to underwriters in an underwritten public offering; 

 (i) advise each selling holder of Restricted Stock, promptly after it shall receive notice
or obtain knowledge thereof, of the issuance of any stop order by the Commission suspending the effectiveness of such registration statement or the initiation or threatening of any proceeding for such purpose and promptly use all reasonable efforts
to prevent the issuance of any stop order or to obtain its withdrawal if such stop order should be issued; 
 (j) cooperate with
the selling holders of Restricted Stock and the managing underwriters, if any, to facilitate the timely preparation and delivery of certificates representing Restricted Stock to be sold, such certificates to be in such denominations and registered
in such names as such holders or the managing underwriters may request at least two business days prior to any sale of Restricted Stock; and 
 (k) permit any holder of Restricted Stock which holder, in the sole and exclusive judgment, exercised in good faith, of such holder, might be deemed to be a controlling person of the Company, to
participate in good faith in the preparation of such registration or comparable statement and to require the insertion therein of material, furnished to the Company in writing, which in the reasonable judgment of such holder and its counsel should
be included, subject to review by the Company and its counsel after consultation with such holder. 
 For purposes of
Sections 7(a) and 7(b) and of Section 4(c), the period of distribution of Restricted Stock in an initial public offering shall be deemed to extend until each underwriter has completed the distribution of all securities
purchased by it, and the period of distribution of Restricted Stock in any other registration shall be deemed to extend until the earlier of the sale of all Restricted Stock covered thereby or 120 days after the effective date thereof. 

It shall be a condition precedent to the obligations of the Company to take any action pursuant to Sections 4, 5, 6
or 7 with respect to Restricted Stock of any selling holder that such holder furnish to the Company in writing such information regarding itself, the Restricted Stock held by it, and the proposed method of distribution of such securities as
shall be necessary to comply with all applicable federal and applicable state securities laws. The Company shall have no obligation with respect to any registration required pursuant to Sections 4 or 6 if the number of shares or the
anticipated aggregate offering price of the Restricted Stock to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate offering price required to originally trigger the Company’s obligation to
initiate such registration under Sections 4 or 6, whichever is applicable. 
 In connection with each registration
pursuant to Sections 4, 5 or 6 covering an underwritten public offering, the Company and each seller agree to enter into a written agreement with the managing underwriter selected in the manner herein provided in such form and
containing such provisions as are customary in the securities business for such an arrangement between such underwriter and companies of the Company’s size and investment stature. 

No Investor shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this
Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 7. 
 8. Expenses. All expenses incurred by the Company in complying with Sections 4, 5 and 6, including, without limitation, all registration and filing fees, printing expenses,
fees and 

 
disbursements of counsel and independent public accountants for the Company, fees and expenses (including counsel fees) incurred in connection with complying with state securities or “blue
sky” laws, fees of the National Association of Securities Dealers, Inc., transfer taxes, fees of transfer agents and registrars, costs of insurance, and reasonable fees and disbursements of one counsel for the sellers of Restricted Stock, but
excluding any Selling Expenses, are called “Registration Expenses.” All underwriting discounts and selling commissions applicable to the sale of Restricted Stock are called “Selling Expenses.” 

The Company will pay all Registration Expenses in connection with each registration statement under Sections 4, 5 or
6. All Selling Expenses in connection with each registration statement under Sections 4, 5 or 6 shall be borne by the participating sellers in proportion to the number of shares sold by each, or by such participating
sellers other than the Company (except to the extent the Company shall be a seller) as they may agree. 
 9. Indemnification
and Contribution. 
 (a) In the event of a registration of any of the Restricted Stock under the Securities Act pursuant to
Sections 4, 5 or 6, the Company, to the extent permitted by law, will indemnify and hold harmless each seller of such Restricted Stock thereunder, each underwriter of such Restricted Stock thereunder and each other person, if
any, who “controls” such seller or underwriter (within the meaning of the Securities Act) against any losses, claims, damages or liabilities, joint or several, to which such seller, underwriter or controlling person may become subject
under the Securities Act, the Exchange Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact
contained in any registration statement under which such Restricted Stock was registered under the Securities Act pursuant to Sections 4, 5 or 6, any preliminary prospectus or final prospectus contained therein, or any amendment
or supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each such seller,
each such underwriter and each such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action, provided, however, that
the Company: (x) will not be liable in any such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in
conformity with information furnished by any such seller, any such underwriter or any such controlling person in writing specifically for use in such registration statement or prospectus or (y) will not be liable for any amounts paid in
settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld or delayed). 

(b) In the event of a registration of any of the Restricted Stock under the Securities Act pursuant to Sections 4, 5 or
6, each seller of such Restricted Stock thereunder, severally and not jointly, will, to the extent permitted by law, indemnify and hold harmless the Company, each person, if any, who “controls” the Company (within the meaning of the
Securities Act), each officer of the Company who signs the registration statement, each director of the Company, each underwriter and each person who “controls” any underwriter (within the meaning of the Securities Act), against all
losses, claims, damages or liabilities, joint or several, to which the Company or such officer, director, underwriter or controlling person may become subject under the Securities Act, the Exchange Act or otherwise, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out 

 
of or are based upon any untrue statement or alleged untrue statement of any material fact contained in the registration statement under which such Restricted Stock was registered under the
Securities Act pursuant to Sections 4, 5 or 6, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof, or arise out of or are based upon the omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and each such officer, director, underwriter and controlling person for any legal or other expenses
reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action, provided, however, that such seller will be liable hereunder in any such case if and only to the extent that
any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information pertaining to such seller, as such,
furnished in writing to the Company by such seller specifically for use in such registration statement or prospectus, and provided, further, however, that the liability of each seller hereunder shall be limited to the proportion
of any such loss, claim, damage, liability or expense which is equal to the proportion that the public offering price of the shares sold by such seller under such registration statement bears to the total public offering price of all securities sold
thereunder, but not in any event to exceed the net proceeds received by such seller from the sale of Restricted Stock covered by such registration statement. 
 (c) Promptly after receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying
party hereunder, notify the indemnifying party in writing thereof, but the omission so to notify the indemnifying party shall not relieve it from any liability which it may have to such indemnified party other than under this Section 9
and shall only relieve it from any liability which it may have to such indemnified party under this Section 9 if and to the extent the indemnifying party is prejudiced by such omission. In case any such action shall be brought against
any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with counsel
reasonably satisfactory to such indemnified party, and, after notice from the indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not be liable to such indemnified
party under this Section 9 for any legal expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation and of liaison with counsel so selected,
provided, however, that, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be reasonable defenses available to it
which are different from or additional to those available to the indemnifying party or if the interests of the indemnified party reasonably may be deemed to conflict with the interests of the indemnifying party, the indemnified party shall have the
right to select a separate counsel and to assume such legal defenses and otherwise to participate in the defense of such action, with the expenses and fees of such separate counsel and other expenses related to such participation to be reimbursed by
the indemnifying party as incurred. 
 (d) In order to provide for just and equitable contribution to joint liability under the
Securities Act in any case in which either (i) any holder of Restricted Stock exercising rights under this Agreement, or any controlling person of any such holder, makes a claim for indemnification pursuant to this Section 9 but it
is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case
notwithstanding the fact that this Section 9 

 
provides for indemnification in such case, or (ii) contribution under the Securities Act is judicially determined (by the entry of a final judgment or decree by a court of competent
jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) to be required on the part of any such selling holder or any such controlling person in circumstances for which indemnification is provided under this
Section 9; then, and in each such case, the Company and such holder will contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from others) in such proportion so that such
holder is responsible for the portion represented by the percentage that the public offering price of its Restricted Stock offered by the registration statement bears to the public offering price of all securities offered by such registration
statement, and the Company is responsible for the remaining portion; provided, however, that, in any such case, (A) no such holder will be required to contribute any amount in excess of the net proceeds received by such holder for
the sale of Restricted Stock registered under such registration statement; and (B) no person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to
contribution from any person or entity who was not guilty of such fraudulent misrepresentation. 
 (e) Notwithstanding the
foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions
in the underwriting agreement shall control. 
 (f) The obligations of the Company and the Investors under this
Section 9 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 9. 
 (g) It is expressly agreed that in accordance with Maryland law, as summarized in Opinion of the Maryland Attorney General No. 86-064 dated December 1, 1986, absent already available
appropriations to fund indemnification or contribution obligations that may arise under this Section 9, any such obligations of the Maryland Department of Business and Economic Development (“DBED”) are conditioned on the
availability of appropriations for use by DBED at the time the indemnification or contribution obligations arise. Any such obligations are further limited to the extent of the State of Maryland’s statutory waiver of its sovereign immunity.

 10. Changes in Common Stock or Preferred Stock. If, and as often as, there is any change in the Common Stock or the
Preferred Stock by way of a stock split, stock dividend, combination or reclassification, or through a merger, consolidation, reorganization or recapitalization, or by any other means, appropriate adjustment shall be made in the provisions hereof so
that the rights and privileges granted hereby shall continue with respect to the Common Stock and the Preferred Stock as so changed. 
 11. Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the Commission which may at any time permit the sale of the Restricted Stock to the public
without registration, at all times after 90 days after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, the Company agrees to: 

(a) make and keep public information available, as those terms are understood and defined in Rule 144 under the Securities Act;

 (b) file with the Commission in a timely manner all reports and other documents required of
the Company under the Securities Act and the Exchange Act; and 
 (c) furnish to each holder of Restricted Stock, so long as
such holder owns Restricted Stock, forthwith upon request (i) a written statement by the Company that the Company has complied with the reporting requirements of such Rule 144, the Securities Act and the Exchange Act, (ii) a copy of the
most recent annual or quarterly report of the Company, and (iii) such other reports and documents so filed by the Company as such holder may reasonably request in availing itself of any rule or regulation of the Commission allowing such holder
to sell any Restricted Stock without registration. 
 12. Right of First Offer. 

(a) Right of First Offer. The Company shall not issue, sell or exchange, agree or obligate itself to issue, sell or exchange, or
reserve or set aside for issuance, sale or exchange, any (i) shares of Common Stock, (ii) any other equity security of the Company, (iii) any debt security of the Company (other than debt with no equity feature) including, without
limitation, any debt security which by its terms is convertible into or exchangeable for any equity security of the Company, (iv) any security of the Company that is a combination of debt and equity, or (v) any option, warrant or other
right to subscribe for, purchase or otherwise acquire any such equity security or any such debt security of the Company, unless in each case the Company shall have first offered to sell such securities (the “Offered Securities”) to the
Major Investors. Each time the Company proposes to offer the Offered Securities, the Company shall first make an offering of such Offered Securities to each Major Investor by delivering a notice by mail (the “Company Notice”) to the Major
Investors stating (i) its bona fide intention to offer such Offered Securities, (ii) the number of such shares of Offered Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such shares of
Offered Securities. Upon delivery of the Company Notice, each Major Investor shall have the right to purchase (x) that portion of the Offered Securities as the number of shares of Restricted Stock then held by such Major Investor bears to the
total number of shares of outstanding capital stock of the Company (assuming the exercise and conversion of all exercisable and convertible securities) (the “Basic Amount”), and (y) such additional portion of the Offered Securities as
such Major Investor shall indicate it will purchase should any other Major Investor subscribe for less than its Basic Amount (the “Undersubscription Amount”), at a price and on such other terms as shall have been specified by the Company
in writing delivered to such Major Investor (the “Offer”), which Offer by its terms shall remain open and irrevocable for a period of 20 days from receipt of the offer. 

(b) Notice of Acceptance. Notice of each Major Investor’s intention to accept, in whole or in part, any Offer made pursuant
to Section 12(a) shall be evidenced by a writing signed by such Major Investor and delivered to the Company prior to the end of the 20-day period of such offer, setting forth such of the Major Investor Basic Amount as such Major Investor
elects to purchase and, if such Major Investor shall elect to purchase all of its Basic Amount, such Undersubscription Amount as such Major Investor shall elect to purchase (the “Notice of Acceptance”). If the Basic Amounts subscribed for
by all Major Investors are less than the total of the Major Investors’ Basic Amounts (such difference, the “Available Undersubscription Amount”), then the Company shall promptly notify each Major Investor which purchases all the
shares available to it of any other Major Investor’s failure to do likewise, whereupon each Major Investor who has set forth Undersubscription Amounts in its Notice of Acceptance shall be entitled to purchase, in addition to the Basic Amounts
subscribed for, all 

 
Undersubscription Amounts it has subscribed for; provided, however, that should the Undersubscription Amounts subscribed for exceed the Available Undersubscription Amount, each
Major Investor who has subscribed for any Undersubscription Amount shall be entitled to purchase only that portion of the Available Undersubscription Amount as the Undersubscription Amount subscribed for by such Major Investor bears to the total
Undersubscription Amounts subscribed for by all Major Investors, subject to rounding by the Board of Directors to the extent it reasonably deems necessary. 
 (c) Conditions to Acceptances and Purchase. 
 (i) Permitted Sales of
Refused Securities. In the event that Notices of Acceptance are not given by the Major Investors in respect of all the Offered Securities, the Company shall have ninety (90) days from the expiration of the period set forth in
Section 12(a) to close the sale of all or any part of such Offered Securities as to which a Notice of Acceptance has not been given by the Major Investors (the “Refused Securities”) to the Person or Persons specified in the
Offer or any other Person or Persons, but only for cash and otherwise in all respects upon terms and conditions, including, without limitation, unit price and interest rates, which are no more favorable, in the aggregate, to such other Person or
Persons or less favorable to the Company than those set forth in the Offer. If the Company does not enter into an agreement for all of the Refused Securities within such ninety (90) day period and if such agreement is not consummated within
sixty (60) days thereafter, the rights provided under this Section 12 shall be deemed to be revived with respect to the Refused Shares not purchased and such unpurchased Refused Shares shall not be offered unless first reoffered to
the Major Investors pursuant to this Section 12. 
 (ii) Closing. Upon the closing, which shall include full
payment to the Company, of the sale to such other Person or Persons of all the Refused Securities, the Major Investors shall purchase from the Company, and the Company shall sell to the Major Investors, the number of Offered Securities determined
pursuant to Section 12(a) and Section 12(b) and upon the terms and conditions specified in the Offer. The purchase by the Major Investors of any Offered Securities is subject in all cases to the preparation, execution and
delivery by the Company and the Major Investors of a purchase agreement relating to such Offered Securities reasonably satisfactory in form and substance to the Major Investors and their respective counsel. Any Offered Securities not purchased by
the Major Investors or other Person or Persons in accordance with this Section 12(c) may not be sold or otherwise disposed of until they are again offered to the Major Investors under the procedures specified in Sections 12(a),
12(b) and 12(c). 
 (d) Termination of Right of First Offer. The rights of the Major Investors under this
Section 12 shall terminate immediately prior to, but subject to, the consummation of the Company’s first firm commitment underwritten public offering of its Common Stock pursuant to the Securities Act (an “IPO”);
provided, however, that the rights of the Investors pursuant to this Section 12 may be waived as to all of such Investors by the affirmative vote or written consent of holders of a majority in interest of the Conversion Shares
held by Major Investors, and any such waiver shall be binding on all Investors, even if any of such Investors do not execute such waiver and irrespective of whether one or more Investors participates in the purchase of the Offered Securities.

 (e) Exception. The rights of the Major Investors under this Section 12
shall not apply to: 
 (i) (a) Common Stock issued as a stock dividend to holders of Common Stock or upon any subdivision or
combination of shares of Common Stock or (b) Preferred Stock issued as a dividend to holders of Preferred Stock upon any subdivision or combination of shares of Preferred Stock; 

(ii) any Common Stock issued in connection with a Qualified Public Offering; 

(iii) any Preferred Shares sold pursuant to the Purchase Agreement; 

(iv) the Conversion Shares; 
 (v) any Reserved Employee Shares; 
 (vi) any securities issued pursuant to the
acquisition of another bona fide commercial operating entity by the Company or any of its Subsidiaries by merger (whereby the Company or any of its Subsidiaries owns no less than 51% of the voting power of such corporation) or purchase by the
Company or any of its Subsidiaries of all or substantially all of such entity’s stock or assets, if such acquisition is approved by the Board of Directors; 
 (vii) any securities issued in connection with a strategic partnership, joint venture or other similar agreement (other than primarily for equity financing purposes), provided that such is approved
by the Board of Directors; 
 (viii) any warrants to purchase Common Stock issued in connection with a bank loan or lease with
a financial institution or the issuance of Common Stock upon the exercise of any such warrant (other than primarily for equity financing purposes) provided that such is approved by the Board of Directors; 

(ix) any securities issued prior to the date hereof; or 
 (x) the issuance of securities pursuant to the conversion or exercise of convertible or exercisable securities either (a) issued prior to the date hereof or (b) if such original convertible or
exercisable securities were subject to the provisions of this Section 12. 
 (f) Assignment. The right of
first offer set forth in this Section 12 may not be assigned or transferred, except that such right is assignable by each Major Investor to any Affiliate of such Major Investor. 

13. Covenants of the Company. 
 (a) Affirmative Covenants of the Company Other Than Reporting Requirements. Without limiting any other covenants and provisions hereof, and except to the extent the following covenants and
provisions of this Section 13(a) are waived in any instance by the holders of at least a majority in interest of the Preferred Shares (voting together as a single class and not as separate series

 
and on an as-converted basis), the Company covenants and agrees that until the consummation of an IPO it will perform and observe the following covenants and provisions, and will cause each
Subsidiary, if and when such Subsidiary exists, to perform and observe such of the following covenants and provisions as are applicable to such Subsidiary: 
 (i) Payment of Taxes and Trade Debt. Pay and discharge, and cause each Subsidiary to pay and discharge, all taxes, assessments and governmental charges or levies imposed upon it or upon its income,
profits or business, or upon any properties belonging to it, prior to the date on which penalties attach thereto, and all lawful claims which, if unpaid, might become a lien or charge upon any properties of the Company or any Subsidiary;
provided, however, that neither the Company nor any Subsidiary shall be required to pay any such tax, assessment, charge, levy or claim which is being contested in good faith and by appropriate proceedings if the Company or any
Subsidiary shall have set aside on its books sufficient reserves, if any, with respect thereto. Pay and cause each Subsidiary to pay, when due, or in conformity with customary trade terms, all lease obligations, all other indebtedness incident to
the operations of the Company or its Subsidiaries, except as such are being contested in good faith and by proper proceedings if the Company or Subsidiary concerned shall have set aside on its books sufficient reserves, if any, with respect thereto.

 (ii) Maintenance of Insurance. The Company shall use its reasonable best efforts to maintain from responsible and
reputable insurance companies or associations a term life insurance policy on the life of each of Rachel King and John Magnani (so long as each remains an employee of the Company), each policy to be in the amount of $2,000,000, the proceeds of which
will be payable to the order of the Company. The Company shall maintain and cause each Subsidiary to obtain and maintain, insurance with responsible and reputable insurance companies or associations in such amounts and covering such risks as is
customarily carried by similarly situated companies engaged in similar businesses and owning similar properties in the same general areas in which the Company or such Subsidiary operates (including Directors and Officers and Errors and Omissions
insurance in amounts and on terms acceptable to the Series A-1 Directors), but in any event in amounts sufficient to prevent the Company or Subsidiary from becoming a co-insurer. Except as otherwise expressly provided herein, the Company will not
cause or permit any assignment of the proceeds of any such insurance policy and will not borrow against any such policy. The Company will add NEA as a notice party to all policies and will request that the issuer(s) of any such policy provide such
designees with at least 10 days’ notice before such policy is terminated (for failure to pay premiums or otherwise) or assigned, or before any change is made in the designation of the beneficiary thereof. 

(iii) Preservation of Corporate Existence. Preserve and maintain, and, unless the Company deems it not to be in its best
interests, cause each Subsidiary to preserve and maintain, its corporate existence, rights, franchises and privileges in the jurisdiction of its incorporation, and qualify and remain qualified, and cause each Subsidiary to qualify and remain
qualified, as a foreign corporation in each jurisdiction in which such qualification is necessary or desirable in view of its business and operations or the ownership or lease of its properties. The Company shall use its reasonable best efforts to
secure, preserve and maintain, and cause each Subsidiary to secure, preserve and maintain, all licenses and other rights to use Intellectual Property Rights owned or possessed by it and deemed by the Company to be material and necessary to the
conduct of its business and the businesses of its Subsidiaries, taken as a whole. 

 (iv) Compliance with Laws. Comply, and cause each Subsidiary to comply, with the
requirements of all applicable laws, rules, regulations and orders of any governmental authority, where noncompliance would have a Material Adverse Change. 
 (v) Inspection. Permit, upon reasonable request and notice, each of the Major Investors or any agents or representatives thereof, provided that the Board of Directors has not reasonably determined
that such Major Investor or any of its Affiliates is a competitor of the Company, to examine and make copies of and extracts from the books of account of, and visit and inspect the properties of the Company and any Subsidiary, to discuss the
affairs, finances and accounts of the Company and any Subsidiary with any of its officers, directors or Key Employees and independent accountants, and consult with and advise the management of the Company and any Subsidiary as to their affairs,
finances and accounts, all at reasonable times during normal business hours. 
 (vi) Confidentiality. Subject to the
disclosure of information of a nontechnical nature, including financial information, which such Investor discloses to its partners and/or shareholders generally and informs such partners and/or shareholders of the confidential nature of such
information and directs them to maintain the confidentiality thereof, each Investor agrees to use, and to use commercially reasonable efforts to ensure that its authorized representatives use, the same degree of care as such Investor uses to protect
its own confidential information (but in no event less than reasonable care) to keep confidential any information furnished to it which the Company identifies as being proprietary or confidential except such information that (a) was in the
public domain prior to the time it was furnished to such Investor, (b) is or becomes (through no action or inaction by any Investor) generally available to the public, (c) was in its possession or known by such Investor without restriction
prior to receipt from the Company, (d) was rightfully disclosed to such Investor by a third party without restriction or (e) was independently developed without any use of, or reference to, the Company’s confidential information.
Notwithstanding the foregoing, each Investor that is a limited partnership that is a bona fide venture capital or private equity fund may disclose summary financial information or a summary overview of the Company’s business (which overview
shall not include any proprietary scientific or technical information) to any former partners who retained an economic interest in such Investor, and to any current or prospective partner, limited partner, general partner or management company of
such Investor (or any employee or representative of any of the foregoing) (each of the foregoing persons, a “Permitted Disclosee”) or legal counsel, accountants or representatives for such Investor or Permitted Disclosee, provided,
however, that any Permitted Disclosee to whom Company confidential information is disclosed shall be subject to the confidentiality provisions of the operating agreements of such Investor (which shall provide that each Permitted Disclosee
shall at least use reasonable care to keep confidential all such confidential information), which operating agreements obligate any such Permitted Disclosee to maintain the confidence of any such confidential information subject to certain
exceptions (which are substantially similar to those contained in (a) through (e) above). Furthermore, nothing contained herein shall prevent any Investor or any Permitted Disclosee from (x) entering into any business, entering into
any agreement with a third party, or investing in or engaging in investment discussions with any other company (whether or not competitive with the Company), provided that such Investor or Permitted Disclosee does not disclose or otherwise make use
of any proprietary or confidential information of the Company in connection with such activities, or (y) making any disclosures required by law, rule, regulation or court or other governmental order, provided that the Company is given
reasonable advance notice of such required disclosure, to the extent reasonably practicable, so that it can take steps (with the Investors’ and Permitted Disclosees’ reasonable cooperation) to prevent or mitigate such disclosure.
Furthermore, DBED agrees that all of the Confidential Information and General 

 
Information constitutes a “trade secret”, “confidential commercial information”, and/or “confidential financial information” for purposes of Section 10-617 of
the State Government Article of the Annotated Code of Maryland, as amended (“Exempt PIA Information”). DBED shall, within 5 business days of receipt, return to the Company any Confidential Information, including any copies thereof or notes
regarding such information in whatever form or media, that DBED does not believe in good faith qualifies as Exempt PIA Information. 
 (vii) Keeping of Records and Books of Account. Keep, and cause each Subsidiary to keep, adequate records and books of account in which true and complete entries will be made in accordance with
generally accepted accounting principles (“GAAP”) consistently applied, reflecting all financial transactions of the Company and any Subsidiary, and including, for each fiscal year, adequate reserves in accordance with GAAP for
depreciation, depletion, returns of merchandise, obsolescence, amortization, taxes, and bad debts. 
 (viii) Maintenance of
Properties. Maintain and preserve, and cause each Subsidiary to maintain and preserve, all of its properties and assets, necessary for the proper conduct of its business, in good repair, working order and condition, ordinary wear and tear
excepted. 
 (ix) Budgets Approval. Not later than 30 days prior to the commencement of each fiscal year, prepare and
submit to, and obtain the approval of the Board of Directors of, a business plan and monthly operating budgets in detail for the upcoming fiscal year, including capital and operating expense budgets, cash flow projections and profit and loss
projections, all itemized in reasonable detail (including itemization of provisions for officers’ compensation). Review the budget and business plan periodically, and resubmit all changes therein and all material deviations therefrom to the
Board of Directors. The Company shall not enter into any activity not in the ordinary course of business and not envisioned by the budget and business plan, unless approved by the Board of Directors. 

(x) Financings. Inform the Board of Directors of any negotiations, offers or contracts relating to possible financings of any
nature for the Company, whether initiated by the Company or any other Person, except for (A) arrangements with trade creditors, and (B) utilization by the Company or any Subsidiary of commercial lending arrangements with financial
institutions. 
 (xi) By-laws. At all times, cause the bylaws of the Company (or the Restated Certificate) to provide
that, unless otherwise required by the laws of the State of Delaware, (i) any two directors and (ii) any holder or holders of at least 25% of the outstanding Preferred Shares, shall have the right to call a meeting of the Board of
Directors or stockholders. At all times maintain provisions in the bylaws of the Company or the Restated Certificate indemnifying all directors against liability to the maximum extent permitted under the laws of State of Delaware. 

(xii) Compliance Agreements. The Company will maintain a duly executed Compliance Agreement (which will endure for a minimum of
one year) in a form as adopted by the Board of Directors with Rachel King and John Magnani and maintain a commercially reasonable confidentiality and assignment of inventions agreement containing customary terms approved by the Board of Directors
with each other employee of the Company and each other independent contractor who has access to the Company’s confidential information. 

 (xiii) New Developments. Cause all officers and Key Employees and, to the best of
the Company’s or any Subsidiary’s ability, consultants of the Company or any Subsidiary, to execute Nondisclosure and Developments Agreements in a form as adopted by the Board of Directors in favor of the Company or any Subsidiary (or, in
the case of consultants in such form and substance as is deemed commercially reasonable by the Key Employee) and, where possible and deemed by management to be commercially appropriate based on the advice of legal counsel and other considerations,
to file and prosecute United States and foreign patent or copyright applications relating to and protecting such developments on behalf of the Company or any Subsidiary. 
 (xiv) Meetings of Directors. Hold meetings of the Company’s Board of Directors not less than four (4) times a year on a quarterly basis. 

(xv) Expenses of Directors. Promptly reimburse in full, each director of the Company who is not an employee of the Company for
all of his reasonable out-of-pocket documented expenses incurred in attending each meeting of the Board of Directors of the Company or any committee thereof. 
 (xvi) Conflicts of Interest. Use commercially reasonable efforts to cause its officers and Key Employees to devote their primary productive time, ability and attention to the business of the
Company. 
 (xvii) Stock Option Plans and Awards. All stock option plans or stock purchase agreements involving
employees, directors or consultants of the Company adopted by the Company from time to time shall provide that each option granted or restricted stock purchased thereunder shall vest (A) with respect to 25% of the shares subject to such grant
or purchase, one year after the date of such grant or purchase and (B) with respect to the remaining shares subject to such grant or purchase, in equal monthly installments over a period of three years thereafter unless otherwise approved by
the affirmative vote of (x) the Board of Directors, or (y) the Compensation Committee of the Board of Directors (which Compensation Committee shall at all times be comprised of at least one of the Series A-1 Directors). 

(xviii) Qualified Small Business Stock. Use reasonable efforts to ensure that the Restricted Stock will meet each of the
requirements for qualification as “qualified small business stock” set forth in Section 1202(c) of the Code. Submit to the Company’s stockholders (including the Investors) and to the Internal Revenue Service any reports that may
reasonably be required under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In addition, within 10 days after any Investor’s written request therefor, deliver to such Investor information in the
Company’s possession which is reasonably requested by such Investor to enable such Investor to determine whether such Investor’s interest in the Company constitutes “qualified small business stock” as defined in
Section 1202(c) of the Code. 
 (xix) Real Property Holding Corporation. The Company shall provide prompt notice to
NEA following any “determination date” (as defined in Treasury Regulation Section 1.897-2(c)(1)) on which the Company becomes a United States real property holding corporation. In addition, upon a written request by NEA, the Company
shall provide NEA with a written statement informing NEA whether NEA’s (or its Affiliates) interest in the Company constitutes a United States real property interest. The Company’s determination shall comply with the requirements of
Treasury Regulation Section 1.897-2(h)(1) or any successor regulation, and the Company shall provide timely 

 
notice to the Internal Revenue Service, in accordance with and to the extent required by Treasury Regulation Section 1.897-2(h)(2) or any successor regulation, that such statement has been
made. The Company’s written statement to NEA shall be delivered to NEA within 10 days of NEA’s written request therefor. The Company’s obligation to furnish such written statement shall continue notwithstanding the fact that a class
of the Company’s stock may be regularly traded on an established securities market or the fact that there is no preferred stock then outstanding. 
 (xx) Indemnification Matters. The Company hereby acknowledges that one (1) or more of the directors nominated to serve on the Board of Directors by the Investors (each a “Fund
Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees
(a) that it is the indemnitor of first resort (i.e., its obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities
incurred by such Fund Director are secondary), (b) that it shall be required to advance expenses incurred by such Fund Director pursuant to the Indemnification Agreement between such Fund Director and the Company (the “Indemnification
Agreement”), and shall, to the extent provided in the Indemnification Agreement, be liable for all expenses, judgments, penalties, fines and amounts paid in settlement by or behalf of any such Fund Director to the extent legally permitted and
as required by the Restated Certificate or the bylaws of the Company (or the Indemnification Agreement), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes
and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund
Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be
subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 
 (b) Negative Covenants of the Company. Without limiting any other covenants and provisions hereof, the Company covenants and agrees that, until the consummation of a Qualified Public Offering or,
while this Agreement remains outstanding, it will comply with and observe the following covenants and provisions, and will cause each Subsidiary, if and when such Subsidiary exists, to comply with and observe such of the following covenants and
provisions as are applicable to such Subsidiary, and will not, without the written consent or waiver of the holders of at least a majority in interest of the holders of the Preferred Shares (voting together as a single class and not as separate
series and on an as-converted basis): 
 (i) Assumptions or Guaranties of Indebtedness of Other Persons. Assume,
guarantee, endorse or otherwise become directly or contingently liable on, or permit any Subsidiary to assume, guarantee, endorse or otherwise become directly or contingently liable on (including, without limitation, liability by way of agreement,
contingent or otherwise, to purchase, to provide funds for payment, to supply funds to or otherwise invest in the debtor or otherwise to assure the creditor against loss) any indebtedness of any other Person, except for trade accounts of the Company
or any Subsidiary arising in the ordinary course of business. 

 (ii) Change in Nature of Business. Except as authorized by the Board of Directors,
make or permit any Subsidiary to make, any material change in the nature of its business as contemplated in written materials delivered to the Investors prior to the date hereof. 

(iii) Ownership of Subsidiaries. Except as authorized by the Board of Directors, purchase or hold beneficially any stock, other
securities or evidences of Indebtedness in, or make any investment in any other Person, excluding a wholly-owned Subsidiary of the Company, if the aggregate financial commitment of the Company related to all such commitments involves more than
$10,000 in any 12-month period. 
 (iv) Issuance of Reserved Employee Shares. Grant to any of its employees options or
other rights to purchase Reserved Employee Shares unless authorized by the Company’s Board of Directors or its Compensation Committee (which Compensation Committee shall at all times be comprised of at least one of the Series A-1 Directors).

 (v) Dealings with Affiliates and Others. Other than as contemplated by this Agreement or as set forth in
Section 4.09 of the Schedule of Exceptions to the Purchase Agreement as delivered at the Closing (as defined in the Purchase Agreement), other than transactions in the ordinary course of business involving less than $25,000, enter into, after
the date of this Agreement, any transaction, including, without limitation, any loans or extensions of credit or royalty agreements, with any officer, director or affiliate of the Company or any Subsidiary or any member of their respective immediate
families or any corporation or other entity directly or indirectly affiliated with one or more of such officers, directors or members of their immediate families unless such transaction is approved in advance by the disinterested members of the
Board of Directors; provided, however, that the Company shall not enter into any transaction with any officer or director of the Company (or any of their respective affiliates) unless such transaction is also approved in advance
by the disinterested Board of Directors. 
 (vi) Maintenance of Ownership of Subsidiaries. Sell or otherwise dispose of
any shares of capital stock of any Subsidiary, except to another Subsidiary, or permit any Subsidiary to issue, sell or otherwise dispose of any shares of its capital stock or the capital stock of any Subsidiary, except to the Company or another
Subsidiary; provided, however, that the Company may liquidate, merge or consolidate any Subsidiary or Subsidiaries into or with itself, provided that the Company is the surviving entity, or into or with another Subsidiary or Subsidiaries.

 (vii) Transfers of Technology. Transfer any ownership or interest in, or material rights relating to, any of its
material Intellectual Property Rights to any Person or entity which is not a member of the consolidated group of the Company and its Subsidiaries; provided, however, that this Section shall not apply to transfers of Intellectual
Property Rights accomplished in the ordinary course of business. 
 (viii) GlycoTech Agreements. Waive any of its
material rights under any agreements with GlycoTech Corporation (together, the “GTC Agreements”) or relieve any other parties to such agreements of any of their material obligations to the Company under the GTC Agreements. 

(ix) Agreements with Key Employees. Amend any material provision of or waive any of its material rights under any agreement with
any officer or Key Employee of the Company, except to the extent approved by the Board of Directors. 

 (c) Reporting Requirements. As long as an Investor holds at least 1,000,000 Preferred
Shares (as adjusted for stock splits, stock dividends, combinations, subdivisions, recapitalizations and similar events) or until the consummation of an IPO, such Investor shall be entitled to receive the following from the Company; provided, that
the Board of Directors has not reasonably determined that such Investor or any of its Affiliates is a competitor of the Company: 
 (i) Monthly Reports: as soon as available and in any event within 30 days after the end of each calendar month, unaudited financial statements of the Company and its Subsidiaries as of the end of
such month and statements of income and retained earnings of the Company and its Subsidiaries for such month and for the period commencing at the end of the previous fiscal year and ending with the end of such month, setting forth in each case in
comparative form the corresponding figures for the corresponding period of the preceding fiscal year, and including comparisons to monthly budgets, and a cash flow analysis for such month, all in reasonable detail; 

(ii) Quarterly Reports: as soon as available and in any event within 45 days after the end of each of the first three quarters of
each fiscal year of the Company, financial statements of the Company and its Subsidiaries as of the end of such quarter and statements of income and cash flows of the Company and its Subsidiaries for such quarter and for the period commencing at the
end of the previous fiscal year and ending with the end of such quarter, setting forth in each case in comparative form the corresponding figures for the corresponding period of the preceding fiscal year, and including comparisons to quarterly
budgets and a summary discussion of the Company’s principal functional areas, all in reasonable detail and duly certified by the chief financial officer of the Company as having been prepared in accordance with generally accepted accounting
principles consistently applied (subject to year-end audit adjustments); 
 (iii) Annual Reports: as soon as available
and in any event within 90 days after the end of each fiscal year of the Company, a copy of the annual audit report for such year for the Company and its Subsidiaries, including therein consolidated balance sheets of the Company and its Subsidiaries
as of the end of such fiscal year and consolidated statements of income and of the Company and its Subsidiaries for such fiscal year, setting forth in each case in comparative form the corresponding figures for the preceding fiscal year, all such
consolidated statements to be duly certified by the chief financial officer of the Company and by such independent public accountants of recognized national standing approved by the Board of Directors; 

(iv) Budgets: as soon as available after approval by the Board of Directors and in any event no later than 30 days prior to the
end of each fiscal year of the Company, a business plan and monthly operating budgets for the forthcoming fiscal year; 
 (v)
Notice of Adverse Changes: promptly after the occurrence thereof and in any event within 10 business days after each occurrence, notice of any Material Adverse Change in the operations or financial condition of the Company or any material
default in any other material agreement to which the Company is a party; 

 (vi) Written Reports: promptly upon receipt or publication thereof, any written
reports submitted to the Company by independent public accountants in connection with an annual or interim audit of the books of the Company and its Subsidiaries made by such accountants or by consultants or other experts in connection with such
consultant’s or other expert’s review of the Company’s operations or industry, and written reports prepared by the Company to comply with other investment or loan agreements; 

(vii) Notice of Proceedings: promptly after the commencement thereof, notice of all actions, suits, litigations and proceedings
pending or, to the knowledge of the Company, threatened against the Company affecting any of its respective properties or assets, or against any officer or director of the Company or, to the knowledge of the Company, any Key Employee or holder of
more than 5% of the capital stock of the Company, relating to such person’s performance of duties for the Company or relating to his, her or its stock ownership in the Company or otherwise relating to the business of the Company including,
without limiting their generality, actions pending of which the Company is a party or, to the knowledge of the Company, threatened involving the prior employment of any of the Company’s officers or Key Employees in their use in connection with
the Company’s business of any information or techniques allegedly proprietary to any of their former employees; 
 (viii)
Stockholders’ and SEC Reports: promptly upon sending, making available, or filing the same, such reports and financial statements as the Company or any Subsidiary shall send or make available to the stockholders of the Company or file
with the Commission; and 
 (ix) Other Information: such other information respecting the business, properties or the
condition or operations, financial or other, of the Company or any of its Subsidiaries as any such Investor may from time to time reasonably request. 
 (d) Genzyme. For the avoidance of doubt, as of the date of this Agreement, Genzyme Corporation shall not be considered a competitor to the Company for purposes of Sections 13(a)(v) and
13(c) and any determination by the Board of Directors after the date of this Agreement that Genzyme is a competitor to the Company shall be made in good faith. 
 The holders of Restricted Stock hereby covenant and agree that all of the information disclosed to such holders pursuant to the provisions of this Section 13(c) shall be treated in accordance
with Section 13(a)(vi) of this Agreement. 
 14. Miscellaneous. 

(a) All covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the
benefit of the respective successors and assigns of the parties hereto (including without limitation transferees of any Preferred Shares or Restricted Stock), whether so expressed or not, provided, however, that the right of first offer set
forth in Section 12 may be assigned in accordance with Section 12F and the registration rights conferred herein on the holders of Preferred Shares, Conversion Shares or Restricted Stock shall only inure to the benefit of a
transferee of Preferred Shares, Conversion Shares or Restricted Stock if (i) there is transferred to such transferee at least 100,000 shares of Restricted Stock held by such Investor immediately following the final Closing under the Purchase
Agreement (as defined therein) (as adjusted for stock splits, stock dividends, combinations, subdivisions, recapitalizations and the like) to the direct or indirect transferor of such transferee or (ii) such transferee is a partner, shareholder
or Affiliate of a party hereto (including any fund under common investment management with the transferor). 

 (b) All notices, requests, consents and other communications hereunder shall be in writing
and shall be delivered in person, delivered by overnight courier service or mailed by certified or registered mail, return receipt requested, addressed as follows: 
 (i) if to the Company or any other party hereto, at the address of such party set forth in the Purchase Agreement; 
 (ii) if to any subsequent holder of Preferred Shares, Conversion Shares or Restricted Stock, to it at such address as may have been furnished to the Company in writing by such holder; 

or, in any case, at such other address or addresses as shall have been furnished in writing to the Company (in the case of a holder of Preferred Shares,
Conversion Shares or Restricted Stock) or to the holders of Preferred Shares, Conversion Shares or Restricted Stock (in the case of the Company) in accordance with the provisions of this paragraph. 

(c) This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to
matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to its principles of conflicts of laws. 

(d) This Agreement (including the Exhibits hereto, if any) constitutes the full and entire understanding and agreement among the parties
with regard to the subjects hereof and thereof, and supersedes the Prior Investor Rights Agreement in its entirety. This Agreement may not be terminated, amended or modified, and no provision hereof may be waived, without the written consent of the
Company and the holders of at least a majority in interest of the Conversion Shares (except that no written consent shall be required to add additional Investors as signatories to this Agreement as provided in Section 14(k) pursuant to
the Purchase Agreement or a transfer of shares of Restricted Stock pursuant to which rights under this Agreement are validly assigned). 
 (e) This Agreement may be executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 
 (f) The obligations of the Company to register shares of Restricted Stock under Sections 4, 5
or 6 shall terminate on the seventh anniversary of the date of a Qualified Public Offering. 
 (g) If requested in
writing by the underwriters for the IPO, each holder of Restricted Stock who is a party to this Agreement shall agree not to directly or indirectly sell, offer to sell, contract to sell (including, without limitation, any short sale), grant any
option to purchase or otherwise transfer or dispose of any shares of Restricted Stock or any other shares of Common Stock (other than shares of Restricted Stock or other shares of Common Stock being registered in such offering), without the consent
of such underwriters, for a period not to exceed 180 days following the effective date of the registration statement relating to such offering, which period may be extended upon the request of the managing underwriter, to the extent required by any
NASD rules, for an 

 
additional period of up to fifteen (15) days if the Company issues or proposes to issue an earnings or other public release within fifteen (15) days of the expiration of the 180-day
lockup period; provided, however, that all persons entitled to registration rights with respect to shares of Common Stock who are not parties to this Agreement, all other persons selling shares of Common Stock in such offering, all persons
holding in excess of 1% of the capital stock of the Company on a fully diluted basis and all executive officers and directors of the Company shall also have agreed not to sell publicly their Common Stock under the circumstances and pursuant to the
terms set forth in this Section 14(g); and provided, further, however, that any such lock-up agreement shall provide that if the managing underwriter releases any shares from the lock-up with respect to such offering prior to the
scheduled expiration date, the managing underwriter shall contemporaneously release a pro rata portion of the Restricted Stock from such lock-up. 
 (h) Without the prior written consent of the holders of a majority of the Conversion Shares and other than as provided in Section 14(k) below, the Company shall not grant to any third party
any registration rights more favorable than or inconsistent with any of those contained herein, so long as any of the registration rights under this Agreement remains in effect; provided, however, that the Company may grant to a third
party piggy-back registration rights upon the approval of such grant by the unanimous consent of the Board of Directors of the Company, and the addition of additional Investors as signatories to this Agreement shall not constitute a grant
inconsistent with the rights herein. 
 (i) If any provision of this Agreement shall be held to be illegal, invalid or
unenforceable, such illegality, invalidity or unenforceability shall attach only to such provision and shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this Agreement, and this Agreement shall be
carried out as if any such illegal, invalid or unenforceable provision were not contained herein. 
 (j) All shares of
Restricted Stock held or acquired by affiliated entities (including affiliated venture capital funds) or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

(k) Any purchaser of Preferred Stock pursuant to the Purchase Agreement shall become a party to this Agreement by executing and
delivering to the Company a counterpart to this Agreement. Upon such execution and delivery, such purchaser shall be deemed to be an “Investor” hereunder with all of the rights and obligations thereof. The execution and delivery of such
counterparts, and the updates of Exhibit 1.01 as a result thereof, shall not constitute an amendment under Section 14 of this Agreement. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.] 

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	GLYCOMIMETICS, INC.
		
	By:	 	/s/ Rachel King
		 	  

		 	Rachel King
		 	Chief Executive Officer
	
	NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP
		
	By:	 	NEA Partners 10, Limited Partnership, its
		 	General Partner
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	
	
	NEW ENTERPRISE ASSOCIATES 13, L.P.
		
	By:	 	NEA Partners 13, L.P., its general partner
		
	By:	 	NEA 13 GP, LTD, its general partner
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Director
	
	ALLIANCE TECHNOLOGY VENTURES III, LP
		
	By:	 	ATV III Partners, its General Partner
		
	By:	 	  

		 	Name:	 	Michael A. Henos
		 	Title:	 	Manager

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	GLYCOMIMETICS, INC.
		
	By:	 	  

		 	Rachel King
		 	Chief Executive Officer
	
	NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP
		
	By:	 	NEA Partners 10, Limited Partnership, its
		 	General Partner
		
	By:	 	/s/ Charles W. Newhall, III
		 	  

		 	Name:	 	Charles W. Newhall, III
		 	Title:	 	General Partner
	
	NEW ENTERPRISE ASSOCIATES 13, L.P.
		
	By:	 	NEA Partners 13, L.P., its general partner
		
	By:	 	NEA 13 GP, LTD, its general partner
		
	By:	 	/s/ Charles W. Newhall, III
		 	  

		 	Name:	 	Charles W. Newhall, III
		 	Title:	 	Director
	
	ALLIANCE TECHNOLOGY VENTURES III, LP
		
	By:	 	ATV III Partners, its General Partner
		
	By:	 	  

		 	Name:	 	Michael A. Henos
		 	Title:	 	Manager

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	GLYCOMIMETICS, INC.
		
	By:	 	  

		 	Rachel King
		 	Chief Executive Officer
	
	NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP
		
	By:	 	NEA Partners 10, Limited Partnership, its
		 	General Partner
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	
	
	NEW ENTERPRISE ASSOCIATES 13, L.P.
		
	By:	 	NEA Partners 13, L.P., its general partner
		
	By:	 	NEA 13 GP, LTD, its general partner
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Director
	
	ALLIANCE TECHNOLOGY VENTURES III, LP
		
	By:	 	ATV III Partners, its General Partner
		
	By:	 	/s/ Michael A. Henos
		 	  

		 	Name:	 	Michael A. Henos
		 	Title:	 	Manager

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	ATV III AFFILIATES FUND, LP
		
	By:	 	ATV III Partners, its General Partner
		
	By:	 	/s/ Michael A. Henos
		 	  

		 	Name:	 	Michael A. Henos
		 	Title:	 	Manager
	
	  

	Mary K. Mahley
	
	NOVARTIS BIOVENTURES LTD
		
	By:	 	Novartis Venture Fund
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	
	
	GLYCOTECH CORPORATION
		
	By:	 	  

		 	Name:	 	John Magnani, Ph.D.
		 	Title:	 	President and Chief Executive Officer
	
	  

	John Magnani, Ph.D.

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	ATV III AFFILIATES FUND, LP
		
	By:	 	ATV III Partners, its General Partner
		
	By:	 	  

		 	Name:	 	Michael A. Henos
		 	Title:	 	Manager
	
	/s/ Mary K. Mahley
	  

	Mary K. Mahley
	
	NOVARTIS BIOVENTURES LTD
		
	By:	 	Novartis Venture Fund
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	
	
	GLYCOTECH CORPORATION
		
	By:	 	  

		 	Name:	 	John Magnani, Ph.D.
		 	Title:	 	President and Chief Executive Officer
	
	  

	John Magnani, Ph.D.

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	ATV III AFFILIATES FUND, LP
		
	By:	 	ATV III Partners, its General Partner
		
	By:	 	  

		 	Name:	 	Michael A. Henos
		 	Title:	 	Manager
	
	  

	Mary K. Mahley
	
	NOVARTIS BIOVENTURES LTD
	
	By: Novartis Venture Fund
		
	By:	 	/s/ H. S. Zivi
		 	  

		 	Name:	 	H. S. Zivi
		 	Title:	 	Deputy Chairman
	
	GLYCOTECH CORPORATION
		
	By:	 	  

		 	Name:	 	John Magnani, Ph.D.
		 	Title:	 	President and Chief Executive Officer
	
	  

	John Magnani, Ph.D.

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	ATV III AFFILIATES FUND, LP
		
	By:	 	ATV III Partners, its General Partner
		
	By:	 	  

		 	Name:	 	Michael A. Henos
		 	Title:	 	Manager
	
	  

	Mary K. Mahley
	
	NOVARTIS BIOVENTURES LTD
		
	By:	 	Novartis Venture Fund
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	
	
	GLYCOTECH CORPORATION
		
	By:	 	/s/ John Magnani, Ph.D.
		 	  

		 	Name:	 	John Magnani, Ph.D.
		 	Title:	 	President and Chief Executive Officer
	
	/s/ John Magnani, Ph.D.
	  

	John Magnani, Ph.D.

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	U.S. SMALL BUSINESS ADMINISTRATION AS RECEIVER FOR ANTHEM CAPITAL II, L.P.
		
	By:	 	/s/ Thomas G. Morris
		 	  

		 	Thomas G. Morris
		 	Director, Office of SBIC Liquidation
	
	PINTO TECHNOLOGY VENTURES, L.P.
		
	By:	 	Pinto Technology Ventures G.P., L.P.
		 	its General Partner
		
	By:	 	  

		 	Evan S. Melrose, M.D.
		 	Managing Director
	
	MARYLAND DEPARTMENT OF BUSINESS AND ECONOMIC DEVELOPMENT
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	
	
	  

	Lauren M. Nehra
	
	  

	Katie S. Nehra

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	ANTHEM CAPITAL II, L.P.
		
	By:	 	Anthem Capital Partners, LLC
	Its:	 	General Partner
		
	By:	 	  

		 	William M. Gust
		 	Manager
	
	PINTO TECHNOLOGY VENTURES, L.P.
		
	By:	 	Pinto Technology Ventures G.P., L.P.
		 	its General Partner
		
	By:	 	/s/ Evan S. Melrose, M.D.
		 	  

		 	Evan S. Melrose, M.D.
		 	Managing Director
	
	MARYLAND DEPARTMENT OF BUSINESS AND ECONOMIC DEVELOPMENT
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	
	
	  

	Lauren M. Nehra
	
	  

	Katie S. Nehra

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	U.S. SMALL BUSINESS ADMINISTRATION AS RECEIVER FOR ANTHEM CAPITAL II, L.P.
		
	By:	 	  

		 	Thomas G. Morris
		 	Director, Office of SBIC Liquidation
	
	PINTO TECHNOLOGY VENTURES, L.P.
		
	By:	 	Pinto Technology Ventures G.P., L.P.
		 	its General Partner
		
	By:	 	  

		 	Evan S. Melrose, M.D.
		 	Managing Director
	
	MARYLAND DEPARTMENT OF BUSINESS AND ECONOMIC DEVELOPMENT
		
	By:	 	/s/ James L. Henry
		 	  

		 	Name:	 	James L. Henry
		 	Title:	 	Program Director, Office of Finance
		 		 	Programs
	
	  

	Lauren M. Nehra
	
	  

	Katie S. Nehra

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	U.S. SMALL BUSINESS ADMINISTRATION AS RECEIVER FOR ANTHEM CAPITAL II, L.P.
		
	By:	 	  

		 	Thomas G. Morris
		 	Director, Office of SBIC Liquidation
	
	PINTO TECHNOLOGY VENTURES, L.P.
		
	By:	 	Pinto Technology Ventures G.P., L.P.
		 	its General Partner
		
	By:	 	  

		 	Evan S. Melrose, M.D.
		 	Managing Director
	
	MARYLAND DEPARTMENT OF BUSINESS AND ECONOMIC DEVELOPMENT
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	
	
	/s/ Lauren M. Nehra
	  

	Lauren M. Nehra
	
	  

	Katie S. Nehra

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	U.S. SMALL BUSINESS ADMINISTRATION AS RECEIVER FOR ANTHEM CAPITAL II, L.P.
		
	By:	 	  

		 	Thomas G. Morris
		 	Director, Office of SBIC Liquidation
	
	PINTO TECHNOLOGY VENTURES, L.P.
		
	By:	 	Pinto Technology Ventures G.P., L.P.
		 	its General Partner
		
	By:	 	  

		 	Evan S. Melrose, M.D.
		 	Managing Director
	
	MARYLAND DEPARTMENT OF BUSINESS AND ECONOMIC DEVELOPMENT
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	
	
	  

	Lauren M. Nehra
	
	/s/ Katie S. Nehra
	  

	Katie S. Nehra

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	GENZYME CORPORATION
		
	By:	 	/s/ Richard Douglas, PhD
		 	  

		 	Name:	 	Richard Douglas, PhD
		 	Title:	 	Senior Vice President
	
	  

	Claudia Henos
	
	RSN ENTERPRISES LLC
		
	By:	 	  

		 	Name:	 	Ralph Snyderman
		 	Title:	 	
	
	ESTATE OF LANGLEY B. KENZIE. ROSS B. KENZIE, ADMINISTRATOR
	
	  

	Ross B. Kenzie
	Administrator
	
	  

	Ross B. Kenzie

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	GENZYME CORPORATION
		
	By:	 	  

		 	Name:	 	Richard Douglas, PhD
		 	Title:	 	Senior Vice President
	
	/s/ Claudia Henos
	  

	Claudia Henos
	
	RSN ENTERPRISES LLC
		
	By:	 	  

		 	Name:	 	Ralph Snyderman
		 	Title:	 	
	
	ESTATE OF LANGLEY B. KENZIE, ROSS B. KENZIE, ADMINISTRATOR
	
	  

	Ross B. Kenzie
	Administrator
	
	  

	Ross B. Kenzie

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	GENZYME CORPORATION
		
	By:	 	  

		 	Name:	 	Allison Robbins
		 	Title:	 	
	
	  

	Claudia Henos
	
	RSN ENTERPRISES LLC
		
	By:	 	/s/ Ralph Snyderman
		 	  

		 	Name:	 	Ralph Snyderman
		 	Title:	 	President
	
	ESTATE OF LANGLEY B. KENZIE, ROSS B. KENZIE, ADMINISTRATOR
	
	  

	Ross B. Kenzie
	Administrator

 IN WITNESS WHEREOF, the parties have executed and delivered this Amended and Restated
Investor Rights Agreement as of the date first above written. 
  

					
	GENZYME CORPORATION
		
	By:	 	  

		 	Name:	 	Richard Douglas, PhD
		 	Title:	 	Senior Vice President
	
	  

	Claudia Henos
	
	RSN ENTERPRISES LLC
		
	By:	 	  

		 	Name:	 	Ralph Snyderman
		 	Title:	 	
	
	ESTATE OF LANGLEY B. KENZIE, ROSS B. KENZIE, ADMINISTRATOR
	
	/s/ Ross B. Kenzie
	  

	Ross B. Kenzie
	Administrator
	
	/s/ Ross B. Kenzie
	  

	Ross B. Kenzie

 Exhibit 1.01 
 GLYCOMIMETICS, INC. 
 SCHEDULE OF INVESTORS 

 

									
	 Investor
	  	No. of Series A-1
Preferred 
Shares	 	  	No. of Converted
Shares	 
			
	 John Magnani, Ph.D

325 West Side Drive, Apartment 101

Gaithersburg, MD 20878
	  	 	32,918	  	  	 	32,000	  
			
	 GlycoTech Corporation

14915 Broschart Road, Suite 200

Rockville, MD 20850
	  	 	—  	  	  	 	16,000	  
			
	 New Enterprise Associates 10, Limited Partnership

1119 St. Paul Street

Baltimore, MD 21202
	  	 	11,250,850	  	  	 	1,938,193	  
			
	 New Enterprise Associates 13, Limited Partnership

1119 St. Paul Street

Baltimore, MD 21202
	  	 	11,824,058	  	  	 	—  	  
			
	 Alliance Technology Ventures III, L.P.

8995 Westside Parkway

Suite 200
 Alpharetta, GA 30004
	  	 	1,103,540	  	  	 	379,363	  
			
	 ATV III Affiliates Fund, L.P.

8995 Westside Parkway

Suite 200
 Alpharetta, GA 30004
	  	 	11,150	  	  	 	4,431	  
			
	 Novartis Bioventures Ltd.

131 Front Street
 Hamilton HM 12
 Bermuda
	  	 	1,157,267	  	  	 	111,515	  

									
	 Investor
	  	No. of Series A-1
Preferred 
Shares	 	  	No. of Converted
Shares	 
			
	 Mary K. Mahley

c/o Ross Kenzie
 P.O. Box 268
 Derby, N.Y. 14047

rossbk@octhouse.com
	  	 	58,173	  	  	 	26,373	  
			
	 Ross Kenzie

P.O. Box 268
 Derby, N.Y. 14047
 rossbk@octhouse.com
	  	 	19,706	  	  	 	—  	  
			
	 Anthem Capital II, L.P.

16 South Calvert Street, Suite 800

Baltimore, MD 21202
	  	 	1,121,646	  	  	 	232,003	  
			
	 Pinto Technology Ventures, L.P.

1600 Smith Street, Suite 3900

Houston, Texas 77022
	  	 	—  	  	  	 	165,716	  
			
	 Maryland Department Of Business and Economic Development

217 East Redwood Street, 11th Floor
 Baltimore, MD 21202
	  	 	—  	  	  	 	63,995	  
			
	 Katie S. Nehra

c/o N. Partners LLC

12 Blythewood Road

Baltimore, Maryland 21210

Phone: (410) 323- 0492

Fax: (410) 323-6119
	  	 	42,050	  	  	 	6,373	  
			
	 Lauren Nehra

c/o N. Partners LLC

12 Blythewood Road

Baltimore, Maryland 21210

Phone: (410) 323- 0492

Fax: (410) 323-6119
	  	 	42,050	  	  	 	6,373	  
			
	 Estate of Langley H. Kenzie,

Ross B. Kenzie, Administrator

P.O. Box 268
 Derbym NY 14047
	  	 	62,447	  	  	 	—  	  
			
	 Genzyme Corporation

Allison Robbins, MBA, CFA

Genzyme Ventures
 Genzyme Center
	  	 	3,941,352	  	  	 	—  	  

									
	 Investor
	  	No. of Series A-1
Preferred 
Shares	 	  	No. of Converted
Shares	 
	 500 Kendall Street, 12th Floor

Cambridge, MA 02142
	  				  			
			
	 Claudia Henos

8019 Warwick Gardens Lane

University Park, FL 34201
	  	 	39,413	  	  	 	—  	  
			
	 Ralph Snyderman

RSN Enterprises LLC

5800 Ten Springs Lane

Durham, NC 27705
	  	 	19,706	  	  	 	—

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]